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SUMMARY 
Tumor metastasis is a fundamental property of malignant cancer cells and the major cause 
of death in cancer patients. Recent studies indicate that tumor cell invasion and 
metastasis may be initiated by the formation of the actin-rich cell protrusions with ECM 
degradation activity, invadopodia. However, despite extensive research on the biology of 
invadopodia, very little is known about their specific inducers during tumor progression. 
Autotaxin (ATX) is a secreted lysophospholipase whose expression levels within tumors 
correlates strongly with their aggressiveness and invasiveness. ATX produces 
lyosophosphatidic acid (LPA), a phospholipid with known tumor promoting functions that 
acts through the G-protein coupled receptors, LPAi-6. Recently, overexpression of ATX 
and LPA receptors (LPA1-3) has been linked to increased tumor invasion and metastasis in 
vivo, however, the role of other LPA receptors (LPA4-6) as well as the exact mechanisms 
by which ATX induces tumor metastasis remain poorly characterized. 
In order to determine the involvement of ATX and LPA in invadopodia production, we 
used the fibrosarcoma HT-1080 cells stably transfected with ATX or shRNA targeting 
ATX in fluorescent matrix degradation assays. Our results demonstrate that ATX is 
implicated in the production of invadopodia resulting in an increase in both their 
formation and function. Using LPC or LPA, the substrate and product of ATX, we further 
show that invadopodia production is dependent on the production of LPA from LPC. 
Among the LPA receptors, LPA4 has the highest expression in HT1080 cells. Using LPA4 
shRNA as well as agonists and inhibitors of the cAMP pathway, we provide evidence that 
LPA4 signaling through the cAMP-EPAC-Rapl axis, regulates invadopodia formation 
downstream of ATX. Furthermore, inhibition of Racl, a known effector of Rap 1 and 
invadopodia formation, abolished EPAC-induced invadopodia production, suggesting 
downstream participation of Racl. Finally, results using LPA4 shRNA support the 
requirement of this receptor for in vitro cell invasion and in vivo metastasis formation. 
Our results suggest that ATX through LPA4 is a strong inducer of invadopodia formation 
that correlates with the ability of the cells to invade and metastasize. This study also 
revealed an unexpected signaling pathway for cell invasion involving LPA4-driven cAMP 
production and subsequent activation of the EPAC-Rapl-Racl axis. 
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L'AUTOTAXIN INDUIT L'INVASION DES CELLULES CANCEREUSES VIA LE 
RECEPTEUR DE TYPE 4 DE L'ACIDE LYSOPHOSPHATIDIQUE 
RESUME 
La formation des metastases est une propriete fondamentale des cellules cancereuses 
malignes ainsi que cause principale de deces chez les patients atteints de cancer. Des 
etudes recent indique que l'invasion tumorale et la formation des metastases peut etre 
initie par la formation des protrusions riches en actine et capables de degrader la matrice 
extracellulaire, appeles des invadopodes. Cependant, malgre les recherches importantes 
sur la biologie des invadopodes, les informations concernant les initiateurs specifiques de 
ces structures lors de la progression tumorale demeurent limitees. L'autotaxin (ATX) est 
une lysophospholipase secretee dont les niveaux d'expression correlent avec l'agressivite 
et le potentiel invasif des tumeurs. L'ATX produit l'acide lysophosphatidique (LPA), un 
phospholipide implique dans la progression tumorale qui agit par 1'intermediate de 
recepteurs couples aux proteines G, LPAi-6. II a ete recemment demontre que la 
surexpression de l'ATX et des recepteurs LPA1-3 cause une augmentation de l'invasion 
tumorale et de la formation de metastases in vivo, cependant, le role d'autres recepteurs, 
soit les LPA4-6, ainsi que les mecanismes exacts par lesquels l'ATX induit la formation de 
metastases demeurent peu connus. 
Afin d'etudier Pinfluence de l'ATX sur la production d'invadopodes, nous avons 
transfecte des cellules de fibrosarcome, les HT-1080, avec des gene codant soit pour 
l'ATX ou des ARNm interferant. Ces cellules ont ete testees dans des essais de 
production d'invadopodes utilisant de la matrice fluorescente et des techniques 
d'immunofluorescence afin de visualiser de facon simultanee la degradation de la matrice 
et les composantes caracteristiques de ces structures. Nos resultats indiquent que l'ATX 
est impliquee dans la formation et les fonctions des invadopodes . Par l'ajout du LPC ou 
du LPA, le substrat et le produit de l'ATX, nous avons montre que la production 
d'invadopodes est dependante de la production de LPA du LPC. Parmi les recepteurs du 
LPA, le LPA4 possede l'expression la plus elevee chez les cellules HT-1080. Par le biais 
de shARNs specifiques au LPA4 ainsi que d'agonistes et d'inhibiteurs de la voie de 
l'AMPc, nos resultats indiquent que la voie de signalisation AMPc-EPAC-Rapl, induite 
par l'activation du LPA4, regule la formation d'invadopodes en aval de 1'ATX. De plus, 
l'inhibition de Racl, un effecteur connu de Rapl et de la formation d'invadopodes, abolit 
la production d'invadopodes induite par l'activation d' EPAC, suggerant la participation 
de Racl en aval de EPAC. Enfin, les resultats d'experiences utilisant des shARNs du 
LPA4 confirment l'implication de ce recepteur dans l'invasion des cellules in vitro et la 
formation de metastases. 
En conclusion, nos resultats suggerent que l'ATX via le LPA4 est un initiateur puissant de 
la formation d'invadopodes par les cellules tumorales, ce qui correle avec leur habilete a 
former des metastases. Cette etude a egalement revelee l'existence d'une voie inattendue 
de signalisation cellulaire dans l'invasion, impliquant la production d'AMPc dependante 
de LPA4 et l'activation subsequente de l'axe EPAC-Rapl-Racl. 
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1- INTRODUCTION 
1.1 Autotaxin 
1.1.1 Identification and structural characteristics 
Autotaxin (ATX), also known as Nucleotide pyrophosphatase/phosphodiesterase 2 
(NPP2), was originally isolated from the culture medium of human melanoma cells 
(A2058) in 1991 (STRACKE et al, 1992). It was identified as a novel 125-kDa autocrine 
motility stimulating factor with a basic pi of 7.7 +/- 0.2 (STRACKE et al, 1992). 
Following its initial discovery, ATX was identified as one of the seven members of the 
nucleotide pyrophosphatase/phosphodiesterase (NPP) enzyme family due to its homology 
with phosphodiesterases (MURATA et al, 1994). All members of the NPP family have 
structurally related catalytic domains and nucleotide pyrophosphatase/phosphodiesterase 
activity whereby they hydrolyze pyrophosphate or phosphodiester bonds in nucleotides 
and other extracellular molecules. However, the NPP family members have very different 
substrate specificity (JANSEN et al, 2005) and are therefore implicated in diverse 
pathological processes (STEFAN et al, 2005). 
ATX was originally thought to be an integral membrane protein like NPP1 because of 
their overall structural similarity (MOOLENAAR, 2002;STRACKE et al, 1997). 
However, researchers have demonstrated that the N-terminal 27-residue hydrophobic 
domain of ATX is in fact a signal peptide that is removed by a signal peptidase during 
translation (JANSEN et al, 2005). ATX has also been shown to have a more prominent 
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cytoplasmic distribution than NPP1, consistent with its N-terminal hydrophobic domain 
being a signal peptide and not a signal anchor as in NPP1 (JANSEN et al, 2005;KOIKE 
et al, 2006). Following the removal of this pre-peptide, the ATX pro-protein follows the 
classical secretory pathway, where proteins are transported outside the cell from the E.R 
via the Golgi apparatus. This was verified by the fact that ATX secretion was arrested by 
brefeldin A, an inhibitor of such transport (JANSEN et al, 2005). These observations 
were consistent with the finding that the majority of ATX is present in the culture medium 
of several cell types such as Glioblastoma Multiforme cells (JANSEN et al, 2005;KISHI 
et al, 2006). ATX is therefore synthesized as a pre-pro-protein and functions as a 
secreted protein (JANSEN et al, 2005;KOIKE et al, 2006). C-terminal to the peptidase 
cleavage site is a consensus sequence for furin, or related pro-protein convertases such as 
PACE4. It is not known whether cleavage by furin occurs before or after secretion, 
however, this cleavage is not required for ATX secretion (JANSEN et al, 2005;KOIKE et 
al, 2006). The removal of an N-terminal octapeptide by furin, however, is associated 
with enhanced motility stimulating activity of ATX in certain reports (JANSEN et al, 
2005). ATX cleaved by furin was shown to have a 30% increase in activity over the non-
furin cleaved form in HEK293 cells (KOIKE et al, 2006). Three ATX isoforms have 
been found in the medium of cells and have been characterized by Giganti et al (2008) as 
ATX a, p, and y. ATX a, originally discovered in A2058 cells, lacks exon 21; ATXp, a 
splice variant reported in human teratocarcinoma (LEE et al, 1996) lacks exons 12 and 
21; and ATXy (PD-1 a), isolated from brain lacks exon 12. The mRNA transcripts of these 
three isoforms were also shown to have different tissue distributions. ATXp mRNA has 
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high expression in peripheral tissues while ATXy mRNA has highest expression in the 
brain. The ATXa mRNA isoform had the lowest expression levels in both the brain and 
peripheral tissues. The measured activity of ATXa protein was also very low probably 
due to its cleavage by an unknown factor that results in a protein of 55-66kDa with little 
or no enzymatic activity (GIGANTI et al, 2008). 
Besides its pre and pro protein domains, ATX contains a Modulator of Oligodendrocyte 
Remodeling and Focal adhesion Organization (MORPHO) domain implicated in 
oligodendroglial process network formation and focal adhesion organization (DENNIS et 
al, 2008). It also contains an EF-hand-like motif that contributes to the function of the 
MORFO domain, an inactive nuclease-like domain that is essential for the catalytic 
activity of ATX, and two cysteine-rich somatomedin B domains (YUELLING and FUSS, 
2008). The somatomedin B domain, which is derived from the amino terminus of 
vitronectin, forms a presumed binding site for type 1 plasminogen activator inhibitor 
(PAI-1), and urokinase plasminogen activator receptor (uPAR) (SEIFFERT and 
LOSKUTOFF, 1991;SEIFFERT et al, 1994). This suggests a relationship of ATX with 
extracellular matrix proteins. In fact, ATX has recently been shown to contain an integrin 
binding domain (RGD) within its somatomedin B domains, that may be implicated in 
lymphocyte trafficking (KANDA et al, 2008). Finally, ATX has a catalytic domain, 
structurally similar to that of the NPP family, that functions as a lysophospholipase D 
(UMEZU-GOTO et al, 2002). This will be discussed in more detail in the following 
section. The structural domains of ATX are illustrated in Figure 1. 
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Figure 1: The major structural domains of ATX. ATX contains an N-terminal signal 
peptide that is removed during translation. Following this is a consensus sequence for 
furin cleavage that may result in enhance activity of the protein. ATX also has two 
somatomedin B domains, an inactive nuclease-like domain that contains an EF hand loop 
motif, and an ATP binding site. Finally there is a catalytic domain which functions as a 
lysophospholipase D and a MORPHO domain implicated in oligodendrocyte remodeling. 
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1.1.2 Enzymatic activity 
ATX was originally thought to hydrolyze pyrophosphate or phosphodiester bonds in 
nucleotides due to its inclusion in the NPP family (BOLLEN et al, 2000). However, 
autotaxin, has recently been shown to be molecularly identical to extracellular plasma 
lysophospholipase D (lysoPLD), whose activity was first discovered in human plasma in 
1983 (YAMASHITA et al, 1983). LysoPLD is responsible for catalyzing the production 
of Lysophosphatidic acid (LPA) from Lysophosphatidylcholine (LPC) by hydrolysis 
(UMEZU-GOTO et al, 2002), see figure 2. cPA (cyclic phosphatidic acid), an analog of 
LPA and intermediate in LPA formation, can also be produced from LPC by ATX 
(TSUDA et al, 2006). LPC is the main physiological substrate for ATX/lysoPLD. In 
fact, ATX has a 25-fold lower Km and thus higher affinity for LPC than for nucleoside 
substrates, which are the natural substrates for other members of the NPP family (XIE and 
Meier, 2004). ATX/LysoPLD also has a higher affinity for unsaturated acyl-LPCs as 
compared to saturated or ether-linked species (TOKUMURA et al, 1999). ATX, 
interestingly, does not contain the HKD motifs critical for the catalytic activity of the 
phospholipase D (PLD) superfamily (XIE and MEIER, 2004). The hydrolysis of 
lysophospholipids by ATX is instead a metal-assisted reaction that occurs via a 
nucleotidylated threonine at the same catalytic site used for the hydrolysis of nucleotides 
(GIJSBERS et al, 2003). ATX requires a metal ion, such as Co2+, for optimal lysoPLD 
activity. It can also be enhanced by Ca2+ and Mg2+, which may act by stabilizing the 
structure of ATX, by protecting it from thermal denaturation and proteolysis, or by 
regulating the catalytic activity of ATX (TOKUMURA et al, 1998). Plasma ATX is 
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Figure 2: Representation of the production of LPA from LPC by ATX. The lysoPLD 
activity of ATX is responsible for hydrolyzing the bond between choline and the 
phosphate group of LPC. This results in release of choline and LPA. (Modified figure 
from: MILLS and MOOLENAAR, 2003). 
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constitutively active (YUELLING and FUSS, 2008), however, its catalytic activity 
depends on an essential disulfide bridge between the catalytic and nuclease-like domains 
(JANSEN et al, 2009) as well as glycosylation of Asn-524 (JANSEN et al, 2007). 
Human ATX activity can be inhibited by EDTA, phenanthroline and ATP as well as by its 
products LPA, cPA and SIP (BAKER et al, 2006;VAN MEETEREN et al, 2005). LPA, 
generated from LPC, is considered to be responsible for the majority of ATX biological 
effects and will be discussed in the LPA section. 
1.13 Expression and role in normal cells and tissues 
ATX is ubiquitously expressed and is, therefore, synthesized by a variety of normal cells 
and tissues. Particularly high expression of ATX has been found in the brain (MILLS and 
MOOLENAAR, 2003), kidneys and lymph nodes (KANDA et al, 2008). ATX is 
implicated in many processes during normal development such as adipogenesis (SIMON 
et al, 2005), and central nervous system development that includes neurite morphology 
(DENNIS et al, 2005). It is also implicated in intestinal cell motility through activation 
of PLC-gamma and phosphorylation/recruitment of villin (KHURANA et al, 2008). ATX 
has been shown to regulate myelination by controlling cytoskeletal organization and FAK 
phosphorylation in oligodendrocytes (FOX et al, 2004). More recently, ATX has been 
shown to be implicated in immune functions due to the findings that mast cells in 
submucosal connective tissue secrete ATX (MORI et al, 2007) and that ATX was shown 
to promote the entry of lymphocytes into secondary lymphoid organs (KANDA et al, 
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2008). Besides these advancements, the most well known role of ATX is in vascular 
development (KHURANA et al, 2008;SATO et al, 2005). 
ATX has been shown to be essential for blood vessel formation during development. 
ATX deficiency using knockout technology in mice leads to embryonic lethality due to 
impaired vessel formation in the yolk sac and embryo (VAN MEETEREN et al, 2006). 
The vascular defects in ATX deficient mice also resemble those in mice lacking genes 
involved in cell migration and adhesion such as the fibronectin and focal adhesion kinase 
genes. Results of this study indicated that the loss of LPA production and downstream 
GPCR signaling is responsible for the phenotype observed in ATX knockout mice (VAN 
MEETEREN et al, 2006). 
1.1.4 Expression and role in pathologies 
ATX has been implicated in numerous pathologies including Alzheimer's disease, chronic 
hepatitis C, multiple sclerosis, neuropathic pain, obesity and rheumatoid arthritis, but its 
most investigated and presumably most important role is in tumorigenesis (FERRY et al, 
2003;HAMMACK et al, 2004;INOUE et al, 2008a;INOUE et al, 2008b;UMEMURA et 
al, 2006;WATANABE et al, 2007;ZHAO et al, 2008). ATX has been shown to be up-
regulated in malignancies including breast, lung, colon, ovarian, stomach, thyroid and 
brain cancer, correlating with the invasiveness of these cancer cells (KEHLEN et al, 
2004;KISHI et al, 2006;YANG et al, 2002;YANG et al, 1999). ATX has been shown to 
augment cellular characteristics associated with tumor aggressiveness, including cell 
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proliferation, cell survival, cell motility, invasion and angiogenesis. ATX acts 
extracellularly and stimulates the metastatic cascade at multiple levels by acting as a 
tumor cell motility factor as well as a strong inductor of the angiogenic response (NAM et 
al, 2000;NAM et al, 2001). Specifically, ATX-transfected Ras-transformed NIH3T3 
cells were shown to be more invasive, tumorigenic, angiogenic and metastatic than mock-
transfected controls (NAM et al, 2000;NAM et al, 2001). ATX, especially in the 
presence of LPC, has been shown to increase chemotaxis and proliferation in multiple cell 
lines. It has also been demonstrated that several cancer cell lines release significant 
amounts of LPC into the culture medium (UMEZU-GOTO et al, 2002). ATX promotes 
proliferation of A2058, MDA-MB231, CHO-K1 and Edg2-RH7777 cancer cells, but not 
RH7777 cells that lack LPA receptors. Research, therefore, suggests that autocrine or 
paracrine production of LPA via ATX contributes to tumor cell motility, survival and 
proliferation (BRINDLEY, 2004;UMEZU-GOTO et al, 2002). Recently over-expression 
of ATX (or LPA 1-3) has been shown to increase tumor invasion and metastasis of breast 
cancer cells (LIU et al, 2009) while pharmacological inhibition of ATX and LPA 
receptors was shown to decrease cell migration in vitro and cause tumor regression in 
mice (ZHANG et al, 2009) further supporting the role of ATX in cancer progression. 
1.1.5 Regulation of expression 
Although ATX has important roles in tumor progression, mostly due to its aberrant 
expression in various malignant cells (described above), little is known about the factors 
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that regulate its expression in cells. This section will detail the few stimulators and 
inhibitors currently known. 
ATX expression can be induced by retinoic acid in a neuroblastoma cell line with N-myc 
amplification that is responsive to the differentiation inducing effects of retinoic acid 
(DUFNER-BEATTIE et al, 2001). ATX is also one of many genes up-regulated during 
Bmp-2 mediated mesenchymal development (BACHNER et al, 1998) indicating that cell 
differentiation might trigger ATX expression in certain cell lines. Lipopolysaccharide 
(LPS) induces ATX expression in the monocytic THP-1 cells via JNK and p38MAPK, 
resulting in enhanced immune cell migration (LI and ZHANG, 2009). Fibroblast-like 
synoviocytes from patients with rheumatoid arthritis have increased expression of ATX 
that can be down regulated by anti-inflammatory cytokines including IL-ip, IL-4 and 
IFN-y (SANTOS et al, 1996). In thyroid carcinoma cell lines, the growth factors EGF 
and bFGF have been shown to stimulate ATX activity while the anti-inflammatory 
cytokines IL-4, IL-ip and TGF-p reduced its expression (KEHLEN et al, 2004). 
Therefore, pro-inflammatory stimuli seem to increase ATX expression while anti-
inflammatory cytokines have the opposite effect. Expression of a6p4 integrin, which 
correlates with an invasive and migratory phenotype in advanced breast carcinomas, leads 
to increased expression of ATX mediated by up-regulation and activation of NFAT1 that 
binds to the ATX promotor (CHEN and O'CONNOR, 2005). ATX expression is increased 
by more than 100-fold in cells transformed by the viral oncoprotein v-Jun (BLACK et al, 
2004) and Epstein-Barr virus, an oncogenic herpesvirus. Infection of Hodgkin lymphoma 
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cells with EBV also results in induction of ATX (BAUMFORTH et al, 2005). In contrast, 
a candidate tumor suppressor gene for breast cancer, CST6, when expressed in breast 
cancer cells down-regulated the expression of ATX (SONG et al, 2006). Therefore it 
seems that molecular cues associated with cancer progression can induce ATX expression 
while tumor suppressors seem to reduce its expression. Each of the above mentioned 
stimuli have been investigated in very few cell types. Therefore, the precise signaling 
pathways and transcription factors responsible for ATX regulation remain mostly 
unknown so many more studies are needed to define exactly how ATX expression is 
regulated. 
1.2 Lysophosphatidic acid 
1.2.1 Identification 
Lysophospholipids have been known for decades as components in the biosynthesis of 
cells membranes with short half lives that range from seconds to minutes (CHOI et al., 
2010;SHIMIZU, 2009). They were originally thought to act as intracellular messengers 
(GERRARD and ROBINSON, 1984) or to mediate effects due to intrinsic chemical 
properties, such as calcium binding activity (SIMON et al., 1984). However, they were 
later found to have cell signaling roles (VOGT, 1963) and it is now known that most 
bioactive lipids act on cell surface GPCRs to mediate intracellular signaling (SHIMIZU, 
2009). Many lysophospholipids, including LPA, have similar effects on cellular functions 
as polypeptide growth factors (HILL and TREISMAN, 1995). LPA (1 or 2-acyl-sn-
glycerol-3-phosphate), a glycerolysophospholipid, was the first LP to be recognized as a 
major lipid mediator in serum exerting growth factor like activities at submicromolar 
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concentrations (TOKUMURA et al., 1978), including mitogenic and morphological 
effects on many cell types (ISHII et al., 2009). 
LPA has a glycerol backbone, single carbon chain, and a polar headgroup (see figure 2) 
(MEYER ZU HERINGDORF and JAKOBS, 2007). There are multiple molecular species 
of LPA, consisting of acyl- or ether-linked chains with various numbers of carbons and 
degrees of unsaturations. The acyl chain can be esterified at either the sn-1 or sn-2 
position of the glycerol backbone(l-acyl-LPA or 2-acyl-LPA) while ether-linked LPAs 
carry an alkyl or alkenyl linkage at the sn-1 position (1-alkyl-LPA or 1-alkenyl-LPA). 
The biological activities of LPA depend on the carbon chain length and degree of 
unsaturation as well as the position and linkage type of the carbon chain attached to the 
glycerol backbone (MEYER ZU HERINGDORF and JAKOBS, 2007). 
1.2.2 Production and degradation of LPA 
LPA is detected in serum, plasma and many other biological fluids and tissues such as 
saliva (SUGIURA et al., 2002), follicular fluid (TOKUMURA et al., 1999), seminal fluid 
(HAMA et al., 2002), and malignant effusions (WESTERMANN et al., 1998). Major 
cellular sources of LPA include platelets and adipocytes (EICHHOLTZ et al., 
1993;VALET et al., 1998), while postmitotic neurons, lymphoid cells, endometrial cells, 
erythrocytes and cancer cells are also able to produce LPA (AOKI et al., 2008;SMYTH et 
al., 2008;YE, 2008). Therefore, LPA may act as a circulating as well as a locally 
produced paracrine mediator (TAKUWA et al., 2002). LPA is found at a concentration of 
approximately 154pmol in cells, 0.1-6.3 uM in blood and 80-100nM in plasma 
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(HOSOGAYA et al, 2008;KISHIMOTO et al, 2003). As mentioned previously, the 
lysophospholipase D activity of autotaxin is responsible for the majority of LPA produced 
in vivo from the substrate LPC (UMEZU-GOTO et al, 2002). However, other enzymes 
and pathways remain responsible for some LPA production. These other routes of LPA 
synthesis include de novo LPA biosynthesis in cells through intermediate lipid 
metabolism, resulting in intracellular LPA, or liberation and subsequent enzymatic 
conversions of precursor glycerophospholipids, resulting in extracellular LPA (GOETZL 
and An, 1998). Extracellular LPA can be produced by the action of many different 
enzymes including phospholipase Al or A2 (PLA1 or 2), monoacylglycerol kinase or 
glycerol-3-phosphate acyltransferase (PEBAY et al, 2007). PLA1/2 for example 
produce LPA by deacylating phosphatidic acid (PA) that is first generated intracellularly 
from phospholipids or diacylglycerol (AOKI et al., 2008). Figure 3 summarizes the 
pathways of LPA production and degradation. 
LPA has short half-life attributed to its rapid degradation by lipid phosphate phosphatases, 
integral membrane proteins that dephosphorylate LPA to monoacylglycerol (MAG) 
(BRINDLEY et al, 2002), or by acylation of LPA to PA by the action of acyl transferases 
(LPAAT) (YAMASHITA et al, 2001). To counteract these effects, extracellular LPA is 
normally bound to proteins such as albumin, fatty acid binding protein, or gelsolin which 
act to increase the stability and facilitate transport of LPA (AOKI, 2004;GAITS et al., 
1997;MILLS and MOOLENAAR, 2003;PAGES et al, 2001). 
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Figure 3: Production and degradation pathways for LPA. The major producer of LPA in 
vivo is ATX which converts LPC to LPA. Other enzymes that can also produce LPA 
include acylglycerol kinase (AGK) which produces LPA from MAG and PLA1/2 which 
can produce LPA from PA. The two major degradation pathways for LPA are acylation 
by LPA AT resulting in PA and phosphorylation by LPPs resulting in MAG. (Modified 
figure from: MEYER ZU HERINGDORF and JAKOBS, 2007). 
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1.2.3 LPA receptors 
The first evidence of the possible existence of G-protein-coupled receptors (GPCRs) 
specific for LPA was the observation, by van Corven et al. in 1989, that the proliferative 
effects of LPA on fibroblasts were pertussis toxin sensitive and therefore mediated by G-
proteins (VAN CORVEN et al, 1989). GPCRs are 7 transmembrane receptors that 
couple to various trimers of G-proteins to mediate intracellular signaling. Further studies 
also supported the existence of LPA-specific receptors (THOMSON et al., 1994;VAN 
DER BEND et al, 1992). Thomson et al. (1994) found LPA-specific high affinity 
binding sites on cell membranes and suggested that GPCRs could be responsible for 
mediating the LPA binding to membranes and induce a transient increase in intracellular 
Ca2+ levels. Van der Bend et al. (1992) found that a 32P-labeled LPA analog binds to a 
membrane protein of 38-40 kDa in various cells types that was proposed to be a specific 
cell-surface LPA receptor (VAN DER BEND et al, 1992). However, it was not until 
1996 (HECHT et al., 1996) that the first LPA receptor gene was identified in mice during 
the course of studies designed to identify novel GPCR genes associated with the 
production of neurons in mice (CHUN et al, 1999;CHUN, 1999;MASANA et al, 1995). 
LPAi, originally named ventricular zone gene l(vzg-l) due to its increased localization in 
this area of the brain, was also known as endothelial differentiation gene 2 (Edg-2) due to 
its sequence similarity to an orphan receptor called Edg-1 (endothelial differentiation 
gene 1) cloned from endothelial cells (HLA and Maciag, 1990). Edg-2/LPAi was 
subsequently cloned and identified as an LPA receptor in humans in 1997 (AN et al., 
1997). LPAi is a 41 kDA (364 a.a) protein with seven transmembrane domains, in 
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concordance with the structure for GPCRs (CHUN et al, 1999;CONTOS and CHUN, 
1998). In human tissues LPAi is widely expressed in almost all tissues with high 
expression in brain, heart, placenta and digestive tract and lowest expression in liver and 
peripheral blood leucocytes (AN et al., 1998a). Interestingly, LPAi is also expressed in 
several cancers (FURUI et al., 1999) such as HeLa carcinoma, SW480 colorectal 
adenocarcinoma, A549 lung carcinoma, and G361 melanoma, but undetectable in many 
leukemia lines and Burkitt's lymphoma (AN et al., 1998a). 
A second LPA receptor, LPA2, originally known as Edg-4, was subsequently identified 
due to sequence similarity with Edg-2/LPAi (CHUN, 1999;CONTOS and CHUN, 1998). 
In humans, LPA2 is detected in testis, pancreas, prostate, thymus, spleen, and peripheral 
blood leukocytes and is almost undetectable in brain, heart, placenta, and digestive tract 
contrary to LPAi (AN et al., 1998a). Therefore, LPA2 is less widely distributed than LPAi. 
LPA2 has also been found to be expressed in various cancer cell types (AN et al., 1998a). 
A third related gene, Edg-7 now known as LPA3 has 60% amino acid similarity to mouse 
LPAi and 2. LPA3 has a more restricted expression pattern than LPAi and 2, having 
abundant expression only in human testis, prostate, heart and frontal regions of the 
cerebral cortex (IM et al., 2000) as well as pancreas, lung and ovary (BANDOH et al., 
1999;IM et al., 2000). The Edg family has some common structural features such as lack 
of a cysteine residue in the first extracellular loop found in most GPCRs and they share 
50-57% amino acid identity in humans (AN et al., 1998a;ISHII et al., 2009). However, 
signaling induced by these receptors was unable to account for all the cellular effects of 
LPA. The existence of additional receptors was later implied by several reports 
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(CONTOS et al, 2002;HOOKS et al., 2001) due to the fact that cell lines not expressing 
the Edg receptors were shown to have mitogenic responses to LPA. 
Recently, a distinct group of LPA receptors unrelated to the Edg family receptors have 
been identified. In 2003 a fourth LPA receptor (LPA4/p2y9/GPR23) was identified that 
was structurally distant from the Edg receptors (NOGUCHI et al., 2003) (LPA4 will be 
discussed in detail in the LPA4 section). This stimulated the identification of two 
additional LPA receptors, LPA5 and LPA6. These three receptors are more closely related 
to the purinergic receptors (purino-receptor cluster), indicating that they arose from 
different ancestor genes than the Edg family receptors (ISHII et al., 2009). 
LPA5 (GPR92-93) (KOTARSKY et al, 2006;LEE et al, 2006) was an orphan GPCR that 
was identified as an LPA receptor due to its close relation to LPA4 (LEE et al., 2006). 
Low levels of LPA5 mRNA are expressed in embryonic brain, heart, placenta 
(KOTARSKY et al., 2006) and platelets (AMISTEN et al., 2008), while high levels were 
found in small intestine (specifically in the lymphocyte compartment) and moderate levels 
in skin, spleen, stomach, thymus, lung, liver, dorsal root ganglion cells (OH et al., 2008) 
and embryonic stem cells (LEE et al., 2006). 
LPA6 (p2y5), was originally reported in 1996 as an orphan GPCR encoded in an intron of 
the retinoblastoma gene (HERZOG et al., 1996). LPA6 has ubiquitous expression 
including in hair follicle cells, epidermis (PASTERNACK et al., 2008), intestine (LEE et 
al., 2009) and a leukemia cell line (YOON et al., 2006) with high expression in human 
umbilical vascular endothelial cells (HUVECs) (YANAGIDA et al, 2009). 
1.2.4 Signaling pathways 
The major cellular effects mediated by LPA are either growth related or cytoskeletal-
dependent effects (GOETZL and An, 1998). Upon receptor activation, G-alpha subunits 
are separated from G-beta-gamma subunits, which remain together, now in their active 
state bound to GTP (WATTS and NEVE, 2005). The Edg family LPA GPCRs mediates 
effects by coupling to Gi, Gq or G12/13 depending on cell type, receptor expression levels, 
or amounts of available G-proteins (AN et al, 1998b;BANDOH et al., 1999;IM et al., 
2000). LPAi and LPA2 can signal through all three of these G-proteins while LPA3 only 
couples to Gq and Gi (FUKUSHIMA et al, 1998;ISHII et al, 2000)(see figure 4 for an 
overview of the signaling pathways). Signaling by LPA4 will be discussed in further 
detail later and signaling of the newest LPA receptors, LPA5 and LPA6, is less well 
characterized and will not be discussed here. 
Gi, which is pertussis toxin sensitive, mediates inhibition of cAMP production as well as 
stimulation of protein kinases that recruit the ras-raf cascade and activate MAP kinases, 
resulting in proliferation and differentiation. Gi induces FAK (focal adhesion kinase) 
activation leading to focal adhesion formation. PI3K is also activated downstream of Gi 
leading to Akt activation and cell survival or Rac activation and cell migration. Finally, 
tyrosine kinase-dependent induction of tyrosine phosphatases can also be promoted by Gi 
signaling (CHUPRUN etal., 1997;GAITS etal, 1996). 
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Ospoiymerization integrin activation 
Figure 4: Signaling pathways of the LPA receptors. The major LPA signaling pathways 
are illustrated here and include signaling through four different G-protein families, G12/13, 
Gi, Gq, an Gs. Signaling through these G-proteins can activate diverse proteins including 
RhoA, PI3K, Ras, PLC and AC. The major downstream effects of LPA signaling include 
cytoskeletal remodeling, cell migration, stress fiber formation, focal adhesion formation 
and integrin activation. 
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Gq mediates phospholipase C (PLC) activation, liberating inositol triphosphate (IP3) that 
causes mobilization of intracellular Ca2+ that can result in actin depolymerization. PLC 
activation downstream of Gq can also stimulate MAP kinases directly or through 
induction of diacylglycerol (DAG), which activates some PKC isozymes, which in turn 
can activate MAP kinases by activating Raf-1, (GHOSH et al, 1997). Furthermore, 
PKC-6 can activate src kinase activity indirectly through protein tyrosine phosphatase 
alpha (BRANDT et al, 2003). Finally, G12/13 stimulates RhoGTPase pathways that 
contribute to SRE-mediated transcription as well as mediating cytoskeletal dependent 
functions such as stress fiber formation and actin polymerization. G12/13 also promotes 
activation of PLD, PI3K, RhoA and Cdc42 (FROMM et al, 1997). GpY dimers may also 
participate in signaling by recruitment of PLC (BARR et al., 2000;SANKARAN et al., 
1998) and association with PI3K (KUROSU et al, 1997;MAIER et al, 
1999;STOYANOVefa/., 1995). 
1.2.5 Implication in physiological and pathological processes 
LPA signaling is implicated in diverse biological processes that include tissue remodeling, 
wound healing (WATTERSON et al., 2007), angiogenesis, platelet aggregation, 
cardiovascular function, (SMYTH et al., 2008) neurogenesis, myelination, olfaction, 
neuropathic pain, reproduction, adipogenesis, (YE, 2008), and immunomodulation 
(MOOLENAAR et al, 2004;NOGUCHI et al, 2009). For instance, LPA has been 
identified as a main platelet-activating lipid of mildly oxidized LDL and human 
atherosclerotic lesions (SIESS et al, 1999). In platelets, LPA induces human platelet 
shape change and platelet aggregation. LPA signaling is also implicated in neuropathic 
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pain responses and induces neuropathic pain and demyelination of the dorsal root similar 
to what is observed after nerve injury (FUJITA et al., 2007). 
LPA is highly implicated in embryonic development of the nervous system . It is an 
important mediator of physiological and pathological processes in the central nervous 
system and influences all neuronal cell types. Both apoptotic and survival effects of LPA 
have been reported and these opposing effects may be due to concentration differences or 
differential expression of LPA receptors as well as cell maturation and cell density 
(TAKUWA et al., 2002). For example, LPA has been demonstrated to mediate 
proliferative effects and morphological changes in Ventricular Zone neuroblasts 
(CONTOS et al., 2000a;FUKUSHIMA et al., 2000), and to influence neuronal 
differentiation (DOTTORI et al., 2008;SPOHR et al., 2008), including neurite formation 
by differentiating neurons (FUKUSHIMA et al., 2000). LPA was also shown to protect 
Schwann cells from apoptosis (WEINER and CHUN, 1999) and to promote cell survival 
of early postmitotic cortical neurons (KINGSBURY et al., 2003). However, LPA also 
induces growth cone collapse and neurite retraction as well as apoptosis in hippocampal 
neurons (FUKUSHIMA, 2004). Apoptotic effects of LPA are observed in neurons 
cultured for over one week while survival effects are seen in neurons cultured for 1-2 
days (FUJTWARA et al., 2003). 
Another important role of LPA is in reproduction. LPA is found in normal follicular fluid 
suggesting its involvement in normal physiology of ovaries (TOKUMURA et al., 1999). 
LPA may also be involved in male and female reproductive physiology and pathology 
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(TOKUMURA et al., 1999). LPA receptor mediated signaling has been implicated in 
many processes involved in reproduction such as ovarian functions (CHEN et al., 
2008;TOKUMURA et al., 1999), with LPA4 being highly expressed in human and mouse 
ovary (NOGUCHI et al., 2003), spermatogenesis, with degradation of LPA being 
associated with reduced spermatogenesis and LPA1-4 expression in human testis (CHOI et 
al., 2010;NOGUCHI et al., 2003;YE, 2008), fertilization (GARBI et al., 2000), early 
embryo spacing (HAMA et al., 2007;YE et al., 2005), decidualization (SHIOKAWA et 
al., 2000) and pregnancy maintenance (ZIECIK et al., 2008). LPA signaling has also 
been implicated in pathologies of the reproductive system including ovarian, prostate and 
endometrial cancers (LPA2 and MMP-7 implicated) (GUO et al., 2006;HOPE et al., 
2009;SUTPHEN et al., 2004) and endometriosis (WEI et al., 2009;WOCLAWEK-
POTOCKA^a/.,2009). 
These physiological effects of LPA are mediated by signaling through various LPA 
receptors whose effects can be elucidated by use of receptor knockout mice. Knockout 
studies have shown that LPAi is implicated in the initiation of neuropathic pain and is 
important for proliferation of astrocytes. LPAi-null mice display 50% lethality, and 
survivors have abnormal phenotypes such as reduced body size, craniofacial 
dysmorphism and reduced brain mass as well as a suckling defect (CONTOS et al., 
2000a). LPAi, therefore, seems to play an important role in the central nervous system. 
LPA2-null mice show no obvious phenotypic abnormalities and, therefore, might have 
redundant functions with LPAi as they both couple to the same G-proteins (CHOI et al., 
2008). Female LPA3-null mice display delayed embryo implantation, altered embryo 
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spacing, and reduced litter size (YE et al., 2005), suggesting that this receptor is 
implicated in reproductive functioning. 
Finally, the most important role of LPA for this study is in tumor progression. LPA is 
known to be a potent tumor promoting molecule and influences many cellular processes 
implicated in tumorigenesis. LPA has an effect on the cellular motility of cancer cells by 
mediating cytoskeletal rearrangements via the Rho GTPases Rho and Rac (IMAMURA et 
al., 1993;STAM et al., 1998). This leads to stimulation or inhibition of cell migration or 
invasion depending on the cell type. LPA can induce proliferation and mitogenic 
signaling of prostate cancer cells (BUDNIK and MUKHOPADHYAY, 2002). LPA also 
stimulates migration and proliferation of human carcinoma cells (DLD1) as well as their 
adhesion to collagen type I and secretion of endothelial growth factor and IL-8, all of 
which can lead to an increased metastasizing potential of DLD1 carcinoma cells (SHIDA 
et al., 2003). LPA is also present in the ascites from ovarian cancer patients 
(WESTERMANN et al, 1998;XU et al, 1998), and a significant increase in blood LPA 
has been found in patients with ovarian carcinoma at the first stage of this disease, 
suggesting an important contribution of LPA to this pathology (FANG et al., 2000). 
Malignant progression has also been shown to correlate with differential expression of 
various LPA receptor subtypes (CONTOS et al., 2000b). LPAi over-expression in breast 
carcinoma cells leads to metastatic spread to bone (BOUCHARABA et al., 2004), while 
LPAi signaling has been shown to mediate stimulation of motility of human pancreatic 
cancer cells (YAMADA et al., 2004) and induction of metastasis by human colon 
carcinoma cells (SHIDA et al., 2003). LPA2 is over-expressed in invasive ductal 
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carcinoma (KITAYAMA et al, 2004) as well as ovarian cancer (ERICKSON et al, 2001) 
and promotes mitogenic signaling in human colon cancer cells (YUN et al., 2005). 
Finally, LPA3 expression increases the aggressiveness of ovarian carcinoma (YU et al., 
2008). Also, as mentioned in the previous ATX section, over-expression of LPA1-3 
receptors or their pharmacological inhibition results in promotion or inhibition of cancer 
cell invasion, tumor progression, and metastasis (LIU et al., 2009;ZHANG et ah, 2009). 
1.3 LPA receptor 4 
1.3.1 Expression and role in physiological processes 
LPA4/p2y9/GPR23 is widely expressed in embryonic tissues including brain and stem 
cells (LEE et al., 2007). In adults, it is abundant in ovary and is weakly expressed in 
many tissues including pancreas, prostate, spleen, small intestine, colon, skeletal muscle, 
brain, placenta, lung, liver, skin, heart, thymus and bone marrow (NOGUCHI et al., 
2003). Increased mRNA expression has also been documented at implantation sites in the 
uterus (ISHII et al., 2009). The roles of LPA4 in physiology and disease have only started 
to be uncovered. To date, LPA4 has been shown to induce Rho-mediated neurite 
retraction and stress fiber formation as well as cell aggregation and rounding (LEE et al., 
2007;YANAGIDA et al., 2007), AC stimulation leading to increased cAMP levels (LEE 
et al., 2007;NOGUCHI et al., 2003), and Gq and Gi-mediated calcium mobilization (LEE 
et al., 2007;NOGUCHI et al., 2003;YANAGIDA et al., 2007). LPA4 may play a role in 
neuronal development including neurogenesis and neuronal migration as it increases 
cAMP and the transcription factor CREB, which is essential to neuronal differentiation 
(RHEE et al., 2006;YANAGEDA et al., 2007). In a recent study, LPA4, coupled to cAMP, 
24 
has been found to inhibit osteogenic differentiation reducing bone volume and trabecular 
thickness (LIU et al.,) signifying a role in bone homeostasis. 
1.3.2 Implications in cancer 
There is little information to date on the implications of LPA4 in cancer. One study has 
found that LPA4 expression inhibits motility and invasion of B103 neuroblastoma cells, 
which do not endogenously express LPA4. In this study, knockdown of LPA4 in MEFs 
increased cell migration, and LPA4 expression decreased PI3K reducing Akt and Rac 
activation levels while increasing Rho activation. It is important to note that in the cell 
type studied, LPA4 couples only to Gq and G12/13 (LEE et al., 2008). However, another 
recent study has found that expression of the LPA4 receptor can induce transformation 
and anchorage independent growth in Myc/tbx2 -transformed cells. Myc and tbx2 are 
cooperating partners in cell transformation. The authors found that expression of LPA4 
(or LPAi or LPA2) in Myc/tbx2-MEFs induced a transformed phenotype observed by the 
increased ability of the cells to grow in soft agar (anchorage-independent growth) as well 
as inducing tumor formation in vivo when these cells were subcutaneously injected in 
mice. These effects were found to necessitate Gi signaling and activation of PI3K and 
ERK1/2 pathways, particularly with prolonged activation of ERK (TAGHAVI et al., 
2008). Therefore the role of LPA4 in tumorigenesis is currently unclear and probably 
depends on cell type and G-protein coupling. 
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1.3.3 Major signaling pathway 
LPA4 has been shown to be capable of signaling through Gi, activating PI3K and ERK1/2 
(TAGHAVI et al., 2008), G12/13 resulting in Rho activation (LEE et al, 2007) and Gq 
inducing increases in calcium (TAGHAVI et al., 2008). However, the major signaling 
pathway of LPA4, different from those previously discussed for the other receptors, is 
signaling through Gs resulting in the production of cAMP (NOGUCHI et al., 2003). 
1.3.3.1 Production of cAMP 
cAMP (cyclic adenosine 3'.5'-monophosphate) was first identified as a second messenger 
nucleotide found to have a fundamental role in the cellular response to extracellular 
stimuli and, therefore, control a diverse range of cellular processes (ROBISON et al., 
1968). GPCRs appear to be the main receptors responsible for causing an accumulation 
of intracellular cAMP in response to ligand binding. The heterotrimeric G proteins 
coupled to GPCRs regulate ACs (adenylyl cyclases) in response to various cellular 
stimuli. The Gs G-protein activates adenylyl cylclases (as does Gq in some instances) 
while the G; family of G-proteins inactivates ACs (WATTS and NEVE, 2005). These G-
proteins, upon receptor activation, separate from GPy and are converted to their GTP-
bound state in which they can exert their distinctive regulatory functions on ACs (WATTS 
and NEVE, 2005). AC are 12 transmembrane domain proteins which are generally bound 
to the inside of cell membranes. Class HI ACs are responsible for cAMP production 
(WATTS and NEVE, 2005). In humans there are 9 transmembrane AC enzymes (tmAC) 
and one soluble AC (sAC). However, the soluble form occurs primarily in mature 
spermatozoa and will not be further discussed here (JAISWAL and CONTI, 2003;WATTS 
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and NEVE, 2005). Gsa activates ACs by inducing a conformational change in the 
catalytic site upon interaction (SKIBA and HAMM, 1998). Activated AC converts ATP 
(adenosine triphosphate) to cAMP by creation of a cyclic phosphodiester bond with the 
alpha-phosphate group of ATP resulting in increased intracellular cAMP concentrations. 
cAMP can then be converted to AMP by cAMP-specific phosphodiesterases (PDE), see 
figure 5. Growth factors and PI3K can also down-regulate cAMP signaling by activating 
Akt and subsequently PDEs, facilitating the conversion of cAMP to AMP (ROBISON et 
al., 1968; DEGERMAN etal., 1997). 
1.3.3.2 Spatial regulation of effectors 
GPCRs are confined to specific domains of the cell membrane in association with 
intracellular organelles or the cytoskeleton. The ACs that they activate are found anchored 
nearby (JARNAESS and TASKEN, 2007) resulting in targeted cAMP production 
depending on the extracellular ligand and receptor activated. cAMP is further regulated 
through its degradation by cAMP-specific phosphodiesterases (PDEs), the only known 
mechanism of cAMP inactivation (JARNAESS and TASKEN, 2007). The cellular 
localization of PDEs is controlled by anchoring to specific subcellular compartments and 
recruitment into multi-protein signaling complexes, therefore, targeting them to specific 
subcellular locations. This allows increased cAMP concentrations in certain areas of the 
cell and not in others, where it will be degraded instead (JARNAESS and TASKEN, 
2007). The level of intracellular cAMP is, therefore, spatially and temporally regulated 
by the balance between the activities of ACs and cyclic nucleotide PDEs (JARNAESS 
and TASKEN, 2007). 
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cAMP effectors are also spatially regulated. PKA (Protein kinase A/cAMP-dependent 
protein kinase), a major effector of cAMP (to be elaborated in the cAMP effector section) 
is tethered to specific intracellular locations by AKAPs (A-kinase anchoring proteins), 
which anchor the regulatory subunits (see figure 6A). AKAPs are scaffolding proteins 
that form multi-protein complexes to integrate cAMP signaling (SCOTT and 
MCCARTNEY, 1994). There are over 50 members of the AKAP family (WONG and 
SCOTT, 2004) which all have similar functions while being structurally diverse 
(JARNAESS and TASKEN, 2007). These proteins all contain a PKA binding domain and 
a unique targeting domain, with several containing additional interaction sites for 
formation of multivalent signaling complexes (JARNAESS and TASKEN, 2007). Some 
AKAPs are known to interact with both PDEs and PKA for example. Targeting of PKA 
isozymes is important for many physiological processes such as cAMP regulation of ion 
channels in the nervous system, regulation of the cell cycle involving microtubule 
dynamics, steroidogenesis, reproductive function, immune response and numerous 
intracellular transport mechanisms (TASKEN and AANDAHL, 2004). 
EPAC (exchange protein activated by cAMP/cAMP-regulated guanine exchange factor) 
proteins, other effectors of cAMP (see cAMP effector section), are also spatially 
regulated. First these proteins have been shown to also interact with AKAP signaling 
complexes which may be responsible in part for their localization, that requires specific 
anchoring, to various cell compartments such as the cytosol, nucleus, nuclear envelope, 
and plasma membrane, resulting in different cellular functions (PONSIOEN et al., 2009). 
EPAC localization has also recently been found to be directly regulated by cAMP. In a 
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2009 study by Ponsioen et al. the authors found that cAMP binding to EPAC induced 
translocation of EPAC to the plasma membrane due to a conformational change that also 
reveals its catalytic site for Rap activation. The translocation of EPAC was found to be 
due to passive diffusion and depended on its DEP domain and is a dynamic and reversible 
event (PONSIOEN et al, 2009). 
Therefore, cAMP is produced at a specific location, due to receptor and AC 
localization, and its diffusion in the cell is controlled by PDE. This results in targeting of 
increased cAMP to specific effectors, for example, PKA or EPAC, and their associated 
substrates. PKA and EPAC are also anchored close to specific effectors resulting in a 
controlled and specific response to cAMP increases, depending on the receptor activated, 
that will mediate a distinct biological effect. 
1.3.3.3 cAMP effectors and roles in cellular functions 
cAMP has been found to be implicated in virtually all cellular responses such as 
proliferation, differentiation, apoptosis, gene transcription, metabolism, secretion, cell 
division and neurotransmission (CHENG et al., 2008). Therefore, it is also implicated in 
many pathologies including diabetes, heart failure and cancer to name a few (CHENG et 
al., 2008). The response to cAMP is cell type and cell context specific, and in different 
situations can mediate opposing effects. For example, cAMP has been shown to either 
inhibit or stimulate cell proliferation depending on the cell type studied or the stimuli 
used (BEAVO and BRUNTON, 2002;STORK and SCHMITT, 2002). The cAMP effector 
EPAC was shown to induce Akt phosphorylation in WRT cells and macrophages 
increasing gene expression and proliferation (CASS et al., 1999), while in adipocytes 
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EPAC was shown to inhibit Akt phosphorylation thereby reducing proliferation 
(ZMUDA-TRZEBIATOWSKA et al, 2007). cAMP has also been shown to inhibit 
keratinocyte migration (MCCAWLEY et al., 2000) or to enhance it (rWASAKI et al., 
1994), depending on the concentration of cAMP used. The role of cAMP in cancer is 
vague, while it has been shown to inhibit tumorigenesis (O'CONNOR et al., 1998), these 
effects are likely to be cell type and context dependent and it is likely that cAMP can 
mediate opposing effects on tumorigenesis as it does on other cellular processes. For 
example one study has shown that cAMP suppresses MMP-2 activation (LEE et al., 
2006), while another study showed that elevation of cAMP increased the expression and 
activity of MMP-2 (TSURUDA et al., 2004), a molecule known to be implicated in tumor 
cell invasion. The responses to cAMP are mediated by its three main effectors, CNGs 
(cyclic-nucleotide gated ion channel) whose activation by cAMP allows calcium influx, as 
well as PKA and EPAC two intracellular cAMP receptors whose diverse cellular functions 
will be discussed in the following paragraphs. 
PKA is the best known cAMP effector and before the discovery of EPAC it was thought 
to mediate nearly all of the effects of cAMP. PKA is a heterotetramer composed of two 
regulatory subunits that when bound to cAMP dissociate from two catalytic subunits 
releasing the inhibition of PKA activity (KIM et al., 2007). PKA is a broad specificity 
serine/threonine kinase that phosphorylates many different substrates including 
cytoplasmic or nuclear substrates, enzymes and transcription factors (KIM et al., 2007). 
Some of the processes that PKA regulates include metabolism, learning and memory 
(ABEL and Nguyen, 2008), exocytosis (SZASZAK et al, 2008), transcription, cell cycle 
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Figure 6: Overview of cAMP production and major effectors. A) cAMP is produced 
from ATP by AC tSiat is activated by the Gs G-protein of a GPCR. Degradation of cAMP 
is performed by PDE anchored to specific subcellular compartments by AKAPs. The 
three major effectors of cAMP, CNG-ion channels, PKA and EPAC are illustrated here. 
PKA is anchored close to the AC producing cAMP due to the action of AKAPs. B) The 
structural domains of EPAC1 and EPAC2 are shown. C) The cAMP analog 8-pCPT can 
activate EPACs GEF activity. (Figure from: ROSCIONI et al, 2008) 
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progression and apoptosis (LORENOWICZ et al., 2008). For example, PKA inhibits the 
interaction of 14-3-3 proteins with BAD and NFAT to promote cell survival (SASTRY et 
al., 2007). It activates KDELR (endoplasmic reticulum protein retention receptor), which 
promotes retrieval of proteins from Golgi to ER therefore maintaining the steady state of 
the cell (CABRERA et al., 2003). Increased cAMP levels promote survival of neuronal 
cells by inactivating GSK3alpha and beta via PKA-dependent mechanisms and thus 
prevents oncogenesis and neurodegeneration (TANJI et al., 2002). PKA also mediates 
ERK activation controlling cell proliferation, and enhances release of stored energy, 
(lipolysis) (CALIPEL et al., 2006). Finally, PKA phosphorylates many transcription 
factors such as CREB, CREM and ATF1, allowing them to interact with transcriptional 
co-activators CBP and p300 to activate transcription (DANIEL et al., 1998). 
EPAC is the newest member of cAMP regulated proteins. EPAC proteins were originally 
identified in 1998 (DE ROOIJ et al, 1998) as having cAMP binding and GEF (guanine 
exchange factor) domains. To date there exist 2 isoforms of the protein, EPAC-1 and 
EPAC-2 also known as RAPGEF3 and RAPGEF4. EPAC1 protein is widely expressed in 
tissues such as blood vessels, kidney, adipose tissue, central nervous system, ovary and 
uterus but not peripheral leukocytes, while EPAC2 has limited expression mainly in the 
central nervous system (DE ROOIJ et al, 1998;KAWASAKI et al, 1998;KILPINEN et 
al., 2008). Like PKA, EPAC has cAMP regulatory binding sites that, when bound to 
cAMP, allow the protein to be active and therefore mediate its GEF activity. EPAC1 
contains a DEP (dishevelled, Egl-10, pleckstrin) domain responsible for membrane 
anchoring, a cAMP binding domain, and a Ras-association domain (RA). For catalytic 
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dynamics or integrin activation. (Figure from: BOS, 2005) 
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activity, EPAC1 contains a CDC25-homology domain (CDC25-HD) for GEF activity 
with a high specificity for Rapl and 2 (Ras-proximate-1 and 2), and a Ras-exchange motif 
(REM) required for catalytic function. EPAC2 differs by containing an additional cAMP-
binding domain (DE ROOIJ et al., 2000) see figure 6B. Since its discovery over 10 years 
ago, EPAC has been found to mediate many of the effects previously attributed to PKA. 
EPAC has been shown to play an important role in cAMP-mediated insulin secretion, cell 
adhesion, exocytosis/secretion, cell differentiation, proliferation, gene expression, 
apoptosis, neurotransmitter release, heart functions and circadian rhythm (CHENG et al., 
2008;PONSIOEN et al, 2009). Briefly, some of the other EPAC effectors besides Rap 
(which will be discussed in following section), include R-Ras which is implicated in cell 
proliferation, survival and gene expression (JESUS et al., 2006), Rims, which is 
implicated in exocytosis (WANG et al., 1997) and Rit, which is implicated in neuronal 
signaling (ROSCIONI et al, 2008;SHI et al, 2006). 
1.3.3.4 EPAC and Rapl 
The main effectors of EPAC are Rapl and Rap2, members of the Ras-like small GTPases, 
which are activated by EPACs guanine nucleotide exchange factor (GEF) activity and 
have themselves GEF activity for many other proteins. Rap2 has been less well studied 
than Rapl and will not be further discussed here. Rapl can be activated by a variety of 
stimuli that include activated receptor tyrosine kinases, GPCRs and cytokine receptors. 
They can also be activated by other specific GEFs, besides EPAC, that include calcium-
and diacylglycerol-binding guanine nucleotide exchange factor 1 (CalDAG-GEF) (BOS 
et al., 2001). Rapl is best known for its inside out activation of integrins resulting in 
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integrin-mediated cell adhesion. Over-expression of Rapl results in activation of 
integrins and increased adhesion to fibronectin while expression of Spal, a specific 
GTPase activating protein (GAP) for Rapl that results in inactivation of Rapl, causes 
inhibition of cell adhesion (BOS et al, 2003;TSUKAMOTO et al, 1999). Rapl appears 
to regulate integrins by increasing both their affinity (conformational activation) and 
avidity (redistribution of integrins into clusters) (BOS et al., 2003) and appears to be 
capable of regulating all integrins associated with the actin cytoskeleton (ENSERTNK et 
al., 2004). The main Rapl effector directly linked to integrin activation is RAPL 
(regulator of adhesion and polarization enriched in lymphocytes), which is found mainly 
in lymphocytes and regulates homing and adherence of these cells (BOS, 2005). 
The other major effect of Rapl is the regulation of actin dynamics. Some of the Rapl 
effectors implicated in actin dynamics include afadin, a multidomain adaptor protein 
(BOETTNER et al, 2000); Riam (Rapl-GTP-interacting adapter molecule), which is 
implicated in cell spreading and integrin-mediated adhesion as well as binding to profilin; 
VASP (Vasodilator-stimulated phosphoprotein) which is involved in actin regulation; 
Arap3, which has ArfGAP and RhoGAP domains resulting in inactivation of Arf6 and 
RhoA; and finally the Rac specific GEFs Vav2 and Tiaml (BOS, 2005). The interaction 
of Rapl with Vav2 and Tiaml resulting in Racl activation is the most direct link between 
Rapl and actin dynamics. Racl, to be discussed in the following section on invadopodia, 
is a small GTPase of the RhoGTPase family responsible for actin polymerization through 
activation of WAVEs and the Arp2/3 complex (EDEN et al, 2002). Rapl binds to the PH 
domain of Vav2 and Tiaml resulting in translocation of these GEFs to the plasma 
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membrane at sites of cell protrusion in contact with the extracellular matrix (ARTHUR et 
al., 2004). Arthur et al. (2004) have found that Racl is both required and sufficient to 
mediate Rapl induced cell spreading and is therefore an important mediator of Rapl. See 
figure 7 for an overview of Rap activators and effectors. 
Contrary to the other cAMP mediators, Rapl is known to be involved in malignant 
progression. However, like cAMP, this role is not straightforward and Rapl has also been 
shown in certain instances to inhibit cancer progression. When Rapl was originally 
discovered in 1989, it was identified as a gene product that restored a malignant 
phenotype of K-Ras-transformed fibroblasts (KITAYAMA et al., 1989). Since then, other 
studies have supported the role of Rapl in promoting malignancy. For example mice 
deficient for SPA-1, which would lead to uncontrolled Rapl activation, develop myeloid 
disorders that resemble human chronic myelogenous leukemia ((KOMETANI et al., 
2004). Activation of Rapl has also been shown to promote prostate cancer metastasis 
(BAILEY et al., 2009) while Rapl GAP acts as a tumor suppressor gene for pancreatic 
cancer (ZHANG et al., 2006a). Rapl also regulates migration of melanoma cells (GAO 
et al., 2006). However, loss of function mutations of DOCK4, a specific Rapl activator, 
were found in human and mouse tumor cells and transfection of Wild-type DOCK4 into 
these tumor cells reduced their growth and invasion in vivo (YAJNTK et al., 2003) 
suggesting a role of Rapl in inhibition of tumorigenesis. Therefore, it seems that either 
defective or excess Rapl can lead to malignant phenotypes via different biological effects 
on different cell lines. 
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1.4 Invadopodia 
1.4.1 Structure 
In order for cancer cells to metastasize they first need to degrade surrounding ECM and 
cross the basement membrane to enter blood vessels and travel to distance sites in the 
body (WOODHOUSE et al, 1997). Cancer cells have been shown to generate 
protrusions called invadopodia to facilitate their migration and invasion through tumor 
stroma and the basement membrane of blood vessels during the process of metastasis 
(CHEN, 1989; KELLY et al., 1998; WOLF and Friedl, 2009). Invadopodia can be defined 
as actin rich, ventral cell membrane protrusions with proteolytic activity (MUELLER and 
Chen, 1991). Invadopodia contain cortactin and phosphotyrosines, are not confined to 
cell periphery but rather are in proximity to the Golgi, and are directly associated with 
sites of substrate degradation. Invadopodia structures are stable with a long half-life of 
two hours or more. Some of the important molecules found at invadopodial protrusions, 
which will be discussed in more detail later, are integrins, tyrosine kinase signaling 
machinery, proteases, actin and actin-associated proteins (BOWDEN et al, 
1999;MUELLER et al, 1992;MUELLER et al, 1999;NAKAHARA, 1998). However, 
there is no known single specific marker of invadopodia to distinctively distinguish them 
from other structures such as podosomes. 
Invadopodia structures have been shown, by electron microscopy, to originate from 
profound invaginations of approximately 8 urn in width and 2 u.m in depth 
(BALDASSARRE et al, 2003;CHEN, 1989). From these invaginations extend many 
surface protrusions that penetrate into the matrix (invadopodia), with diameters ranging 
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from 100's of nanometers to a few micrometers and a length of approximately 500 nm 
(BALDASSARRE et al, 2003). The connections between these protrusions and the cell 
body have been shown to be very narrow (BALDASSARRE et al, 2006). Another 
important feature in cells producing invadopodia is a polarization and proximity of the 
Golgi toward invadopodial protrusions, suggesting a possible relationship between 
membrane/protein transport and proteolytic activity (BALDASSARRE et al, 2003). 
While the molecular and physiochemical cues that trigger invadopodia biogenesis are not 
well known, one possible mechanism of invadopodia initiation is the activation of 
integrins by their extracellular substrates ((NAKAHARA et al, 1996;NAKAHARA, 
1998). For example, alpha6betal activation promotes Src-dependent tyr phosphorylation 
of pl90RhoGAP affecting the actin cytoskeleton. This activates membrane-protrusive 
and proteolytic activity leading to invadopodia formation and cell invasion (MUELLER 
et al, 1999). The following sections will detail the various components necessary for full 
functioning of an invadopodium. 
1.4.2 Actin remodeling 
Invadopodia are formed as small clusters consisting of a few large actin-rich dots that 
extend into the matrix substratum. Actin remodeling is therefore essential for the 
formation and stability of invadopodial protrusions and involves coordinated action of 
many proteins such as Arp2/3, N-WASP, cortactin, and cofilin to spatially and temporally 
regulate actin polymerization (POLLARD and BORISY, 2003). These proteins which 
have all been either localized to invadopodia or shown to be essential for invadopodia 
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formation (ARTYM et al, 2006;BALDASSARRE et al, 2006;YAMAGUCHI et al, 
2005) will be discussed in greater detail in the following paragraphs. 
The Arp2/3 complex consists of 7 proteins, two related proteins Arp2 and Arp3 along with 
five unique polypeptides ARPC1-5 (GOLEY and WELCH, 2006). When activated, this 
protein complex initiates the nucleation of a new actin filament from an existing filament 
at a 70 degree angle, known as branched actin polymerization (MULLINS et al, 
1998;WELCH et al, 1998). Arp2/3 is, therefore, responsible for actin rearrangement 
implicated in the formation of lamellipodia, filopodia, invadopodia and cell motility in 
general (GOLEY et al, 2004). N-WASP is part of a family including WASP and WAVEs 
that have a common C-terminal catalytic verprolin-cofilin-acidic (VCA) domain essential 
for functional activation of the Arp2/3 complex (MULLINS et al, 1998;WELCH et al, 
1998). WASP family proteins integrate multiple upstream signals to induce actin 
polymerization through the Arp2/3 complex (MILLARD et al, 2004). Their major 
upstream regulators are Cdc42 and Racl (EDEN et al, 2002) however N-WASP is also 
regulated by phosphorylation by Src family kinases. N-WASP is ubiquitously expressed 
and abundant in the brain (MIKI et al, 1998). Besides affecting actin polymerization 
through Arp2/3, N-WASP is also implicated in endocytic and phagocytic processes and 
may promote internalization of degraded matrix components or recycling of invadopodia 
components (INNOCENTI et al, 2005;LORENZI et al, 2000). It is important to note as 
well that dysfunctions of Arp2/3 are associated with cancer metastasis and Arp2/3 and 
WASP family proteins are found to be up-regulated in some tumors and invasive cells 
(OTSUBO et al, 2004;SEMBA et al, 2006;YAMAGUCHI and CONDEELIS, 2007). 
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For example, WAVE2, regulated by Racl, is a primary regulator of melanoma cell 
invasion and metastasis (KURISU et al, 2005). 
Cortactin is another essential element of invadopodia and is often used as a marker 
because cortactin clusters located at the basement membrane near the center of the cell 
and not in the cell periphery are used to identify invadopodia structures (GIMONA and 
BUCCIONE, 2006). Cortactin is an actin-binding and scaffolding protein that 
coordinates cell migration, cytoskeletal remodeling, and intracellular protein transport 
(AMMER and WEED, 2008). The N-terminal acidic domain (NTA) of cortactin contains 
a DDW motif (aspartic acid-aspartic acid-tryptophan motif) that binds and weakly 
activates the Arp2/3 complex directly through the N-terminal region of Arp2/3, or 
indirectly by binding N-WASP via the SH3 domain of WASP and activating it (LUA and 
LOW, 2005;WEAVER et al, 2001). Cortactin also acts by stabilizing branched actin 
filaments and, therefore, regulates actin assembly mediated by Arp2/3 (URUNO et al, 
2001). Cortactin can also bind to dynamin2, via an SH3 domain, Src, via a proline rich 
region and filamentous actin (F-actin) with the fourth of its cortactin repeats (DALY, 
2004). Cortactin was originally identified as a major substrate of Src (WU et al, 1991) 
and is tyrosine phosphorylated in response to stimuli that induce actin cytoskeleton 
remodeling, such as FGF, EGF, or integrins. Phosphorylation of some of its tyrosines, 
Y421/466/482 in the proline rich domain (PRD) has been shown to be required for 
motility and metastatic dissemination of breast cancer cells (LI et al, 2001). 
Phosphorylation of cortactin by Src might influence the interactions of actin nucleators 
and actin turnover. As well Src phosphorylation of cortactin is important for invadopodia 
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function (ARTYM et al, 2006). Along with its cytoskeletal remodeling functions 
cortactin might also regulate MMP secretion at sites of degradation, another critical 
component of invadopodia to be discussed in the next section (CLARK et al, 2007). 
Cortactin is ubiquitously expressed, however, as with the other proteins discussed thus 
far, cortactin is frequently up-regulated in many cancers including breast, head and neck 
carcinoma, and bladder cancer (SCHUURING, 1995). 
Cofilin is a member of the actin depolymerizing factor (ADF)/cofilin family and is a 
small ubiquitous protein (19kDa). Cofilin is able to bind monomeric and filamentous 
actin (PAAVILAINEN et al, 2004). It is an essential regulator of actin dynamics at the 
plasma membrane through its ability to sever actin filaments resulting in disassembly of 
F-actin from the rear of migrating cells and recycling of actin monomers to the leading 
edge for further polymerization (PAAVILAINEN et al, 2004). Depletion of cofilin 
results in small, short-lived and, therefore, poorly degrading invadopodia. Cofilin, 
therefore, seems to have a role in stabilization and/or the maturation process of 
invadopodia (YAMAGUCHI et al, 2005). Cofilin is also implicated tumor cell invasion 
and metastasis (WANG et al, 2007). 
Finally invadopodia are also enriched with integrins, which form bridges between the 
cytoskeleton and ECM potentially linking the two aspects necessary for fully functional 
invadopodia, formation and matrix degrading activity (CHEN, 1990). 
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1.4.3 ECM degradation 
Degradation of the extracellular matrix (ECM) constitutes the function of invadopodia. 
This process requires many proteases to physically degrade ECM proteins. It also needs 
membrane trafficking to sustain prolonged degradation by transporting protease-
delivering carriers from the Golgi to the ECM as well as an appropriate substrate (ECM) 
that can affect the activity of invadopodia depending on its rigidity, matrix density and 
cross-linking (ALEXANDER et al, 2008;CALDIERI et al, 2009a). 
The majority of proteolysis at invadopodial structures is due to the metalloproteinase 
family, which includes matrix metalloproteinases (MMPs) and ADAMs (a disintegrin and 
metalloproteinase). There are over 25 members of the MMP family that are broadly 
divided into membrane and soluble types that together can degrade virtually all ECM 
components (EGEBLAD and WERB, 2002). MMPs are synthesized as inactive 
proenzymes that become activated through proteolytic removal of their pro-domain (VAN 
HINSBERGH et al, 2006). Membrane-type 1 MMP (MT1-MMP), which degrades 
collagen, fibronectin and laminins is one of the most important enzymes for invadopodia 
functions (NAKAHARA et al, 1997). It has been shown to be a master regulator of 
protease-mediated cell invasion through activation of a cascade of proteases including the 
gelatinase MMP-2 (HOLMBECK et al, 2004). MT1-MMP over-expression or 
knockdown results in an increase or decrease of invadopodia formation and function 
(ARTYM et al, 2006;NAKAHARA et al, 1997). Therefore, recruitment of MT1-MMP 
to invadopodia might establish the focused zone of MMP activation around this structure. 
Two gelatinases MMP-2 and MMP-9 have also been localized to invadopodia and are 
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known to degrade type IV collagen, a major component of basement membrane 
(REDONDO-MUNOZ et al, 2006). Interestingly MMPs might also play a role in 
invadopodia formation as broad-spectrum MMP inhibitors abolish formation and not just 
functioning of invadopodia (AYALA et al, 2008;BALDASSARRE et al, 2006). The 
other members of the metalloprotease family are ADAMs. They function as sheddases 
(enzymes that cleave proteins at the cell surface leading to the release of ectodomains) 
and cleave growth factors and cytokine precursors into their active forms while their 
disintegrin domain interacts with integrins especially the betal component (HUOVILA et 
al, 2005). 
Serine proteinases are also implicated in invadopodia-mediated degradation. Seprase and 
DPP4 (dipeptidyl dipeptidase IV) are transmembrane serine peptidases implicated in 
ECM degradation and shown to colocalize with invadopodia (GHERSI et al, 2006). 
These two serine proteases are activated by oligomerization and are also able to bind 
betal integrins in a collagen dependent manner and degrade collagen, fibronectin, and 
laminins (MONSKY et al, 1994). Seprase and DPP4 are also up-regulated in melanoma 
and breast carcinoma cells (CHEN, 2003). The urokinase-type plasminogen activator 
(uPA) proteolytic system has also been implicated in invadopodia (ARTYM et al, 
2002;KTNDZELSKII et al, 2004). uPAR (urokinase-type plasminogen activator receptor) 
is found in a complex with seprase at sites of invadopodia formation and activates 
plasminogen which can subsequently activate various MMPs (LIJNEN, 2001). Matrix 
degrading proteases also activate and release growth factors such as VEGF (Vascular 
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endothelial growth factor) locally from the matrix, which might enable continued 
induction of invadopodia through receptor signaling (EBRAHEM et al, 2010). 
1.4.4 Signaling 
Signaling plays a major role in coordinating the formation and functioning of 
invadopodia. Activation of integrins and receptor tyrosine kinases induces intracellular 
cascades involving PKC, Src, Rho GTPases and tyrosine kinases for invadopodia 
generation. Some of the most important signaling pathways involve tyrosine kinases, 
such as Src and Src-family kinases whose role in invadopodia has been well established. 
In fact, tyrosine phosphorylation is a marker of invadopodia and SFK activity is 
absolutely required for invadopodia formation and degradation (MUELLER et al, 1992). 
Serine/threonine kinases such as ERK1/2 and PAK have also been implicated in 
invadopodia biogenesis possibly playing a role in cortactin phosphorylation (AYALA et 
al, 2008;TAGUE et al, 2004). The ARF-family of GTPases are also involved as they 
control actin rearrangement (AL-AWAR et al, 2000) and have been localized to 
invadopodia (TAGUE et al, 2004). 
Finally, the most important signaling molecules for this study are the Rho family 
GTPases. These are small G-proteins that when activated exchange GDP for GTP 
resulting in a conformational change that allows them to interact with downstream 
effectors. This active state is later terminated by hydrolysis of bound GTP to GDP 
(BISHOP and HALL, 2000). Among their various effector targets are protein kinases and 
actin nucleators allowing them to influence cell shape, morphology, polarization, motility 
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and metastasis formation (HALL, 2005). Most Rho GTPases act on various cellular 
membranes and affect the morphology of these membranes through alterations of the 
associated cytoskeleton. Many also affect specific steps of vesicle trafficking between 
different intracellular compartments (MATOZAKI et al, 2000). They are also usually 
activated on membranes by GEFs (ROSSMAN et al, 2005). Post-translational 
modifications are also critical for RhoGTPase interaction with membranes (ex 
prenylation, palmitoylation) and can enhance their interaction with various cellular 
membranes and define their localization to specific membrane compartments 
(CUSHMAN and CASEY, 2009). Phosphorylation also regulates activity and localization 
of some Rho GTPases such as RhoA (ROSSMAN et al, 2005). 
Racl and Cdc42 can both activate Arp2/3 through their effectors Sra-1 and N-WASP 
respectively. Cdc42 binds WASP specifically through WASPs CRIB domain and Cdc42 
binding results in unfolding of the protein making the VCA domain accessible to Arp2/3 
(CALDIERI et al, 2009a). Cdc42 in particular has been shown to act upstream of 
invadopodia formation with DA mutants inducing dot-like degradation (NAKAHARA et 
al, 2003). RhoA has also been suggested to play a role due to the fact that pl90Rho-
GAP activates membrane protrusive activity (NAKAHARA et al, 1998). All of these 
GTPases require GEFs (stimulate release of GDP allowing GTP to bind), GAPs (catalyze 
GTP hydrolysis converting to GDP) and GDIs to function efficiently and many GEF have 
been identified as oncogenes (ROSSMAN et al, 2005). While Racl has not been directly 
related to invadopodia formation, it can induce actin polymerization through activation of 
Arp2/3 and could be implicated in recruitment of cortactin, both essential to invadopodia 
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formation (BAUMER et al, 2008). ROCK as well as Racl and Cdc42 also activate 
PAKs, which phosphorylate and activate LIMKs which then phosphorylate cofilin to 
permit its role in actin dynamics at invadopodia (AYALA et al., 2008;CALDIERI et al, 
2009a). 
Finally, there are also numerous adaptor molecules and effectors downstream of these 
signaling cascades that are localized to and regulate invadopodia such as cortactin, 
(GIMONA and BUCCIONE, 2006); dynamin2, a large GTPase which regulates actin 
organization via cortactin (KRUCHTEN and MCNIVEN, 2006), and also has a 
specialized function in tubulation and constriction of cell membranes and, therefore, 
affects membrane trafficking (BALDASSARRE et al, 2003); Tks5, a scaffolding protein 
and Src substrate that binds and modulates N-WASP (OIKAWA et al, 2008); IQGAP1, 
which regulates Cdc42 and Racl modulating cytoskeletal architecture (NABESHIMA et 
al, 2002); and Paxillin, a scaffolding protein that coordinates the actions of Rho GTPases 
and forms a complex with cortactin at invadopodia (BOWDEN et al, 1999), to name a 
few. Figure 8 provides an overview of the structure of an invadopodium and many of the 
proteins implicated. 
1.4.5 Implication of invadopodia in metastatic process 
Invadopodia are considered to be an in vitro model for cell invasion due to the fact that 
focal delivery of proteases is crucial for physiological ECM remodeling events and tumor 
cell invasion (BASBAUM and WERB, 1996). Focal ECM degradation requires tight 
coordination between polarized trafficking, signaling events and cytoskeletal/membrane 
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remodeling and invadopodia are likely the place where this integration occurs (GIMONA 
and BUCCIONE, 2006). Furthermore, invadopodia biogenesis correlates highly with 
well-established assays for invasive capability such as invasion through matrigel-coated 
transwell chambers and xenograft metastasis models (BOWDEN et al, 1999;COOPMAN 
et al, 1998;THOMPSON et al, 1992). Invadopodia-like structures formed by migrating 
cancer cells undergoing intravasion have been imaged by multiphoton microscopy while 
whole animal imaging has allowed real-time visualization of invadopodia-like protrusions 
in tumor cells invading through tissues (CONDEELIS and SEGALL, 
2003;YAMAGUCHI et al, 2005). Enrichment of invadopodia markers such as cortactin 
and Tks5 have also been found at the invading front of human tumors in tissue samples, 
consistent with invadopodia-mediated invasion (SEALS et al, 2005;ZHANG et al, 
2006b). In summary, invadopodia are organelles where many functions associated with 
cancer aggressiveness converge such as tyrosine kinase signaling, protease secretion and 
targeting, and cytoskeletal rearrangement and may, therefore, reveal to be good 
therapeutic targets. Also, these structures are not important for cell viability and their 
disruption may, therefore, have less side effects than some of the current treatments 
(WEAVER, 2006). 
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Figure 8: Invadopodium. A plasma membrane protrusion is formed due to excessive 
actin polymerization induced by RhoGTPases signaling. Various molecules are 
implicated in this actin polymerization including N-WASP, Arp2/3 and cortactin. 
Cortactin can be further activated by Src which may be found in focal adhesion 
complexes containing FAK and integrins, in close proximity to invadopodia. 
Metalloproteinases including MMP-2 and MMP-9 are secreted at invadopodia and can be 
activated by MT1-MMP which is enriched at invadopodia membrane protrusions. 
(ARSENAULT, D. Unpublished) 
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1.5 Objectives and pertinence 
Autotaxin has been implicated in the invasiveness and metastatic potential of numerous 
cancer cell lines (KEHLEN et al, 2004;KISHI et al, 2006;YANG et al, 2002;YANG et 
al., 1999). It is responsible for producing the majority of LPA in vivo, which in turn 
signals by activating GPCRs (BRINDLEY, 2004;UMEZU-GOTO et al, 2002). Over-
expression of ATX or LPA receptors has recendy been linked to increased tumor invasion 
and metastasis of breast cancer cells (LIU et al., 2009). Similarly, knockdown of ATX 
and LPA receptors has been shown to inhibit tumor cell migration and cause tumor 
regression in mice (ZHANG et al., 2009). These results suggest an important role for 
ATX and LPA receptors in cancer progression and tumor metastasis, however the precise 
signaling pathways and cellular effects involved remain largely unknown. In order for 
cancer cells to metastasize, they first need to degrade surrounding tissues. Invadopodia 
are invasive subcellular structures formed by cancer cells that are increasingly being 
recognized as important mediators of matrix degradation necessary for cell invasion and 
metastasis (CONDEELIS and SEGALL, 2003;YAMAGUCHI et al, 2005). The 
formation of these structures requires specific signaling events and recruitment of 
effectors, which are slowly being unraveled (YAMAGUCHI et al., 2006). The hypothesis 
of mis research was that ATX, through LPA production and LPAR signaling, induces the 
formation of the invasive structures, invadopodia, leading to metastasis of cancer cells. 
The objectives of this research were to evaluate the implication of ATX and LPA on 
invadopodia production and to determine the receptor and signaling pathways used to 
promote invadopodia and metastasis formation. 
The first objective of the research presented in this memoire was to determine the 
involvement of ATX and LPA in invadopodia production. For this, we transfected cells 
with ATX or shRNA against ATX. We then investigated the response of these cells in 
invadopodia assays. We also studied the effects of LPC and LPA on various cancer cell 
types in invadopodia assays. The second objective of this memoire was to establish 
whether LPA receptors were implicated in invadopodia production and to define the 
receptor(s) implicated. For this, we used a broad-spectrum inhibitor of LPA receptors and 
observed the effects on invadopodia production. We also measured the mRNA expression 
levels of the various LPA receptors in the HT1080 cell line. In addition, we used LPA4 
shRNA to study the requirement of this receptor for invadopodia production. The effect 
of LPA4 knockdown on in vitro cell invasion and in vivo metastasis formation was also 
studied, using a 3D invasion assay and a lung metastasis assay, respectively. The third 
objective of this research was to ascertain the downstream signaling pathways involved in 
ATX-induced invadopodia. As LPA4 primarily couples to Gs, resulting in increased 
intracellular cAMP concentrations, we investigated signaling by the cAMP pathway. For 
this, we evaluated the effect of various activators and inhibitors of cAMP and its 
downstream effectors in the invadopodia assay. 
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2 - ARTICLE 
2.1 Preface 
The manuscript presented in this memoire entitled "Autotaxin Promotes Cancer Invasion 
via the Lysophosphatidic Acid Receptor 4: Participation of the cAMP/EPAC/Racl 
Signaling Pathway in Invadopodia Formation" presents the results of research performed 
in the context of my master's program. This article has been accepted for publication in 
the peer reviewed journal, Cancer Research and will appear in the June issue. The 
authors of this article are Kelly Harper, Dominique Arsenault, Stephanie Boulay-Jean, 
Annie Lauzier, Fabrice Lucien and Claire M. Dubois. The form for authorization of 
integration of an article into a memoire with signatures from all authors is attached. I 
personally performed the bibliographic research, experimental planning and the majority 
of the experiments. I also wrote and participated in the correction of the manuscript. 
Dominique Arsenault, a Ph.D. student, performed the experiments represented in Figure 
6A and 6B as well as helping capture images for figure 1. Stephanie Boulay-Jean, a 
stagiaire, performed the experiment presented in figure 2D. Annie Lauzier, a post-
doctoral student, performed the western blot presented in figure 4D. Fabrice Lucien, a 
master's student, participated in the WB presented in figure 2C. Dr. Claire Dubois is my 
research director. It was with her guidance that I planned the experiments and developed 
this project. 
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2.2 RESUME 
L'habilete des cellules cancereuses a envahir les tissus et former des metastases est la 
cause principale de deces chez les patients atteints de cancer. L'autotaxin (ATX) est une 
lysophospholipase secretee dont les niveaux d'expression correlent avec l'agressivite et le 
potentiel invasif des tumeurs. L'ATX est l'enzyme majeure impliquee dans la production 
de l'acide lysophospatidique (LPA), un phospholipide qui est connu pour agir 
principalement par l'intermediare de recepteurs LPA1-3. L'invasion des cellules tumorales 
et la formation des metastases sont dependantes de la capacite des cellules cancereuses a 
degrader la membrane basale. Ce processus peut etre initie par la formation de protrusions 
riches en actine, appelees invadopodes. Dans cette etude, nous demontrons que l'ATX est 
impliquee dans la formation des invadopodes chez divers types cellulaires cancereux. Cet 
effet est dependant de la production de LPA. De plus, nous montrons que la signalisation 
via le LPA4 chez les cellules de fibrosarcome regule la formation des invadopodes en aval 
de l'ATX, c'est a dire a travers l'activation de EPAC par PAMPc et l'activation ulterieure 
de Rac-1. Les resultats utilisant l'ARN interferent du LPA4 renforce l'idee que le 
recepteur LPA4 est necessaire a l'invasion cellulaire et la formation de metastases in vivo. 
Ce travail suggere que le blocage du recepteur au LPA, LPA4, dans les cellules de 
fibrosarcome pourrait etre une avenue interessante afin d'ameliorer l'efficacite du 
traitement des metastases chez les patients atteints de cancer. Du fait que les recepteurs au 
LPA et l'ATX sont actuellement des cibles therapeutiques pour des essais precliniques, 
ces decouvertes devraient stimuler des etudes ulterieures visant a evaluer le profil 
d'expression et Tissue clinique du LPA4, en conjoncture avec les autres recepteurs au 
LPA, dans plusieurs types de cancers. 
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Abstract 
The ability of cancer cells to invade and metastasize is the major cause of death in cancer 
patients. Autotaxin (ATX) is a secreted lysophospholipase whose level of expression 
within tumors correlates strongly with their aggressiveness and invasiveness. ATX is the 
major enzyme involved in the production of LPA, a phospholipid that is known to act 
mostly through its three first characterized receptors, LPA1-3. Tumor cell invasion across 
tissue boundaries and metastasis are dependent on the capacity of invasive cancer cells to 
breach the basement membrane. This process can be initiated by the formation of the 
actin-rich cell protrusions, invadopodia. In this study, we demonstrate that ATX is 
implicated in the formation of invadopodia in various cancer cells types and this effect is 
dependent on the production of LPA. We further provide evidence that LPA4 signaling in 
fibrosarcoma cells regulates invadopodia formation downstream of ATX, a process 
mediated through the activation of EPAC by cAMP and subsequent Rac-1 activation. 
Results using LPA4 shRNA support the requirement of the LPA4 receptor for cell invasion 
and in vivo metastasis formation. This work presents evidence that blocking the LPA 
receptor, LPA4, in fibrosarcoma cells could provide an additional tool to improve the 
efficacy of treatment of metastasis in patients. Because LPA receptors and ATX are 
currently being targeted in preclinical trials, the current findings should stimulate future 
studies to evaluate the expression pattern and clinical outcome of LPA4, together with 
other LPA receptors, in various cancer patients. 
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Introduction 
Cancer remains a leading cause of death worldwide despite relendess efforts in 
basic research and clinical management of the disease. Autotaxin (ATX), a secreted 
motility stimulating factor that was originally isolated from the culture supernatant of 
human melanoma cells (A2058) (1), has been linked with progression of many types of 
cancer. Up-regulation of ATX in malignancies including breast, lung, colon, ovarian, 
stomach and brain cancer was correlated with invasiveness and metastatic potential (2-4). 
ATX has been found in many biological fluids including blisters, cerebrospinal, peritoneal 
and, synovial, as well as plasma (5-8). Through its extracellular actions, ATX augments 
cellular functions closely associated with tumor aggressiveness and metastasis that 
include proliferation, survival, motility, invasion and angiogenesis (9,10). ATX has 
recently been shown to be molecularly identical to lysophospholipase D, which catalyzes 
the production of the majority of lysophosphatidic acid (LPA) from 
lysophosphatidylcholine (LPC) in vivo (11). Consequently, LPA is thought to be 
responsible for the majority of ATXs effects (12). LPA is a bioactive lipid and a major 
constituent of serum whose effects are similar to those of ATX (11,13). LPA is also 
implicated in many pathophysiological conditions such as atherosclerosis, hypertension, 
ischemia reperfusion injury, and, pertinent to this study, cancer (14). LPA mediates cell 
type-specific responses by engaging high affinity G-protein-coupled receptors (GPCRs) 
(15). 
There are currendy six known LPA receptors. LPAi - LPA3 are members of the 
endothelial differentiation gene (edg) receptor family whereas the more recently de-
orphaned LPA4-LPA6 belong to the purigenic cluster of GPCRs (16-18). Most research 
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has focused on the first identified LPA receptors while the signaling and physiological 
roles of LPA4 -LPA6 have received less attention. LPA signals via at least four distinct G-
protein families, Gi, Gq, G12/13, and Gs and their downstream effectors. The major 
signaling pathways that become activated include the PI3K and Ras pathways which 
depend on Gi, PLC which depends on Gq, Rho GTPases which are associated with G12/13 
signaling and cAMP production downstream of Gs (13,19). Many of these signaling 
routes have been shown to be involved in tumor survival and invasion. (19). Over-
expression of ATX and LPA receptors (LPA1-3) has been recently linked to increased 
tumor invasion and metastasis of breast cancer cells (20). Moreover, pharmacological 
inhibition of both ATX and LPA receptors (mostly LPA1-3) has been shown to decrease 
cell migration in vitro and cause tumor regression in mice (21). These studies uncovered 
an important role for ATX and LPA1-3 receptors in tumor metastasis, a fundamental 
property of malignant cancer cells and the major cause of death in patients. 
Metastatic tumor cells must first degrade the surrounding tissues and reach the 
blood stream to travel to distant sites and form new tumors. Cancer cells have been 
shown to generate protrusions called invadopodia to facilitate their migration and 
invasion through tumor stroma and the lining of the blood vessels during the process of 
metastasis (22,23). Invadopodia are formed by highly invasive cancer cells. They are 
actin-rich ventral membrane protrusions which possess ECM degrading activity (24). The 
formation of these structures necessitates the convergence of many different signaling 
pathways and molecules, which are slowly being unraveled. Besides actin, invadopodia 
contain actin regulatory proteins, adhesion molecules, membrane remodeling and 
signaling proteins and extracellular matrix-degrading enzymes (25). The Rho GTPases, 
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including Racl and Cdc42, have repeatedly been shown to promote invadopodia 
production through their actions on the cytoskeleton (26). Formation of invadopodia is 
enhanced by extracellular matrix rigidity (27), some growth factors such as EGF (22) or 
expression of wild-type or activated forms of the src tyrosine kinase (28). Therefore, 
despite much research on invadopodia biology, very little is known about specific 
inducers and receptors during tumor progression. 
Because of the implications of ATX and LPA signaling in metastasis and their 
activation of pathways, which could be implicated in invadopodia formation, we have 
investigated the involvement of ATX and LPA receptors in invadopodia production. 
Using the invasive fibrosarcoma cell line, HT1080, we observed that ATX through the 
LPA4 receptor is a strong inducer of invadopodia formation that correlates with the ability 
of the cells to invade and metastasize. This study also revealed an unexpected signaling 
pathway for cell invasion involving LPA4-driven cAMP production and subsequent 
activation of the EPAC-Rapl-Racl axis. 
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Materials & Methods 
Reagents. l-oleoyl-s«-glycerol-3-phosphate sodium salt 18:1 (LPA),L-cc-
lysophosphatidyl choline from egg yolk (LPC-egg), l-oleoykw-glycero-3-
phosphocholine 18:1 (LPC-18:1), 2'-0-dibutyryladenosine 3 ' , 5'-cyclic monophosphate 
sodium (dibutyryl cAMP), 8-(4-chlorophenylthio)-2'-0-methyladenosine 3'-5'-cyclic 
monophosphate monosodium hydrate (8-pCPT), 8-bromoadenosine 3'-5'-cyclic 
monophosphate sodium (8-bromo cAMP), H-89 dihydrochloride hydrate, LPAreceptor 
antagonist (KH6425), forskolin, cholera toxin (CTX), and pertussis toxin (PTX) were 
purchased from Sigma-Aldrich (St. Louis, MO). The Racl inhibitor NSC23766 and Rapl 
inhibitor GGTI-298 were from Calbiochem (EMD Chemical Inc, La Jolla, CA) and 
myristoylated PKI (14-22) amide (PKI) was from Biomol International LP (Plymouth 
Meeting, PA). ATX cDNA construct and ATX antibody (84A) were a kind gift from Dr. 
Tim Clair (Center for Cancer Research, NCI, NIH). shRNA against ATX, LPA4, or EPAC 
was from SABiosciences (Frederick, MD). The anti-tubulin antibody was from Sigma-
Aldrich, the anti-cortactin antibody was from Millipore (Temecula, CA), the anti-EPAC 
antibody was from Cell signaling (Boston, MA) and Texas Red phalloidin and all 
secondary antibodies were from Invitrogen (Molecular Probes, Eugene, OR). 
Cell culture and transfections. HT1080 human fibrosarcoma, MDA-MB231 and MCF-7 
human breast cancer, A549 human lung cancer and U87 human glioblastoma were 
obtained from the American Type Culture Collection (ATCC, Rockville, MD). All cell 
lines were cultured in minimal essential medium (MEM) (Wisent, St-Bruno, QC, Canada) 
supplemented with 10% FBS (Gibco BRL, Burlington, ON, Canada) and 40/<g/ml of 
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gentamycine (Shering Canada Inc., Pointe-Claire, QC, Canada) in a humidified 95% air/ 
5% CO2 incubator at 37°C. Stable transfections with ATX cDNA or shRNA against ATX, 
LPA4 or EPAC shRNA, or scramble shRNA (negative control) were performed with the 
Fugene reagent from Roche Diagnostics (Mannheim, Germany), according to the 
manufacturer's protocol. 
Real time RT-PCR. Total RNA was isolated using the TRI-Reagent (Invitrogen, Carlsbad, 
CA) protocol as previously described (29) and quantitative Real-Time PCR was 
performed on a Rotor-Gene 3000 (Corbett Research, Kirkland, QC, Canada). The 
following primer pairs were selected for LPA4: (forward) 5'-AAAGATCATGTACCCAA 
TCACCTT-3', (reverse) 5^-CTTAACAGGGACTCCATTCTGAT-3' and for human acidic 
ribosomal phosphoprotein PO (RPLPO): (forward) 5'-GATTACACCTTCCCACTTGC-
3', (reverse) 5'-CCAAATCCCATATCCTCGTCCG-3'. The cycling program was: initial 
denaturation at 95°C for 15 min, 40 amplification cycles with denaturing T° of 95°C for 30 
s, annealing T° of 55°C for 30 s and final extension at 72°C for 30 s. 
Western blotting. Cells were lysed on ice in RIPA buffer. Supernatant samples were 
recovered by centrifugation (13000rpm for 30min at 4°C) and protein concentration was 
determined using the BCA reagent (Biolynx Inc, Brockville, ON). Immunoblotting was 
performed as previously described (30). 
Invadopodia assays. Coverslips were prepared as previously described (31), using 
Oregon-green gelatin (Invitrogen, ON, Canada). Thirty thousand cells were seeded on 
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each coverslip, allowed to adhere and incubated in MEM with 0.5% FBS. Following 
various incubation times as described within the figure legends, cells were fixed with 1% 
paraformaldehyde for 30 min at 4°C and stained with DAPI (Invitrogen) for 5 min at 
room temperature. Cells were visualized by fluorescence microscopy and cells forming 
invadopodia were counted. Invadopodia were identified by areas of matrix degradation 
characterized by loss of green fluorescence. Three X 100 cells were counted per 
coverslip. 
Fluorescence Microscopy. Cells were grown on gelatin coated coverslips and fixed with 
1% paraformaldehyde in PBS for 30 min at 4°C, permeabilized with 0.05% saponine 
(Sigma-Aldrich) in PBS for 20 min and blocked with 2% BSA in PBS for 30 min. For 
calculation of the number of invadopodia per cell, cells were then incubated with anti-
cortactin antibody for 2 h, secondary antibody 488-conjugated anti-mouse for 1 h at 4°C 
followed by Texas Red phalloidin for 45 min and DAPI for 5 min. Colocalization of actin 
and cortactin was visualized using an Axioskop 2 phase-contrast/epifluorescence 
microscope and 20 cells were counted per condition (Carl Zeiss, Inc., Thornwood, NY). 
Images were taken with a FV1000 scanning confocal microscope (Olympus, Tokyo, 
Japan) coupled to an inverted microscope using a 63x oil immersion objective. To 
quantify the areas of degradation, pictures of fluorescent gelatin were acquired and 
captured into ImagePro imaging software (MediaCybernetics) and degradation areas were 
calculated in pixels for a total of at least 20 cells per coverslip. 
3D invasion assays. The 3D invasion assay was modified from a previously described 
technique (32). Collagen type I matrix was prepared as follows: Aliquots (50 jxL) of 
Agarose containing 10% FBS were deposited in a 96 well culture plate. Aliquots (50 jih) 
of fibrillar collagen type I (R&D Systems, Minneapolis, MN) were then prepared 
following manufacturer's instructions and layered on top of the Agarose. Cells 
(2xl04/100/d of serum-free MEM) were deposited on top of the collagen gel and 
incubated for 36 h. The cells were then labeled with CellTrace™ calcein green AM 
(Invitrogen) lh prior the end of incubation. Cells were then washed with PBS and fixed 
with 3% glutaraldehyde for 30 minutes followed by confocal microscopy analysis using a 
FV1000 Olympus confocal microscope. Collagen matrix pellets were scanned along the 
Z axis. Cells that had invaded the collagen were imaged and quantitated at each 5 }im 
layers within the gel. 
In vivo metastasis assay. Mice were housed and manipulated under pathogen free 
conditions, in accordance with the guidelines of the local institutional animal care facility. 
Experimental metastatic potential of HT1080 transfected cells was measured by the lung 
colonization assay. Briefly, 2 x 105 cells in 0.1 ml of PBS were injected into the tail vein 
of 5- to 7-week-old female CD1 nude mice. Twenty-nine days later the mice were 
sacrificed and the lungs were fixed with Bouin's solution (Sigma-Aldrich). Metastatic 
colonies on the lung surface were counted macroscopically. 
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Results 
Autotaxin induces the formation of matrix degrading invadopodia through the 
production of LPA from LPC. 
Since ATX is upregulated in many cancer cell lines and its expression correlates 
with cell invasion (2-4), we investigated whether ATX is implicated in invadopodia 
production. As shown in Fig. 1A, ATX over-expression in HT1080 human fibrosarcoma 
cells induced a significant 5-6 fold increase in the percentage of invadopodia producing 
cells as compared to parental HT1080 cells. Furthermore, the over-expression of ATX 
resulted in a significant increase of the gelatin degradation area (Fig. IB), as well as the 
number of invadopodia formed per cell identified by colocalization of actin and cortactin, 
two known markers of invadopodia (28) (Fig. 1C). Confocal microscopy analysis of ATX 
degradation areas showed that they were associated with cell membrane protrusions, 
which were characterized by punctate actin cores that extended from the basal membrane 
of the cell into the underlying matrix (Fig. ID). These observations suggested that ATX is 
involved in both invadopodia formation and function. 
To determine whether the impact of ATX was due to the ability of the enzyme to 
produce LPA from LPC, HT1080 cells were incubated in the presence or absence of LPC 
or LPA during the invadopodia assay. Results showed concentration-dependent increases 
in the percentage of invadopodia-producing cells after lOh of incubation (Figs. 2A and B), 
showing that both the substrate and the product of ATX enzymatic activity have the 
ability to induce the production of invadopodia. Next, depletion of ATX by shRNA 
abolished LPC- but not LPA-induced invadopodia formation (Fig. 2C), confirming that 
LPC-derived LPA was a key metabolite in invadopodia production. We further 
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Figure 1. Autotaxin induces invadopodia formation in HT1080 cells 
Parental and ATX-overexpressing HT1080 cells were cultured on fluorescent gelatin for 
10 h (A and B), or on non-fluorescent gelatin for 4 h (C). A, The percentage of 
invadopodia-producing cells are shown; n=3-9. Representative images of parental and 
ATX-transfected cells with associated matrix degradation are shown (10X magnification). 
B, Quantification of ECM degradation area/cell; n=3, with representative images of 
degradation by parental and ATX transfected cells (40X magnification). C, Number of F-
actin (green) and cortactin (red) positive invadopodia per cell; n=2, with representative 
confocal images showing colocalization of actin and cortactin spots (magnification 60X). 
D, A representative confocal image of ATX-transfected cells showing actin-rich 
invadopodia that extend into the matrix substratum (F-actin, red; gelatin, green). 
Columns, mean; bars, SEM; ***,p < 0.0001. 
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investigated whether the findings observed in the HT1080 cell line applied to other 
malignant cell lines. LPC induces invadopodia production in MDA- MB231 (breast 
cancer), A549 (lung cancer), CaCo2 (colon cancer) and U87 (glioblastoma) cell lines. In 
contrast, MCF-7(breast cancer), that has an intrinsic defect in cell invasion, failed to 
respond to LPC (Fig. 2D). These results indicate a role for ATX in the formation of 
invadopodia by a wide range of neoplastic cells. 
LPA receptor 4 is implicated in the formation of invadopodia through the activation 
of the Gs-cAMP-EPAC pathway. 
Since the cellular effects of LPA are due to its binding and activation of various 
LPA-specific GPCRs (15) and some of these receptors have been linked to tumor invasion 
(20, 21), we further investigated the role of these receptors and their downstream 
signaling pathways in mediating the effects of ATX and LPA on invadopodia production. 
Treatment of ATX over-expressing cells with a broad spectrum LPA receptor antagonist 
(Ki 16425) resulted in a significant decrease in invadopodia production (Fig. 3A), 
suggesting an important role for these receptors in transducing the ATX/LPA-dependent 
invasive function. We next assessed the relative expression levels of the most 
characterized LPA receptors (LPA1-4) in HT1080 cells to identify which of the receptors 
were more likely to mediate the effects of ATX/LPA on invadopodia production. In 
agreement with previously published results (2), HT1080 cells expressed high levels of 
LPA4 with only a minimal expression of LPA1-3 (Fig. 3B). Next, to further assess the role 
of LPA4 in invadopodia production, HT1080 cells were transfected with LPA4 shRNA. 
Results showed that LPA4 inhibition abolished invadopodia production induced by LPA or 
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Figure 2. ATX-induced invadopodia production is dependent on LPA production 
from LPC 
A and B, HT1080 cells were cultured for lOh with various concentrations of LPC-18:1 
(A) , or LPA (B) and the percentage of invadopodia-producing cells was calculated; 
n=3-4. C, parental HT1080 or cells transfected with ATX shRNA or ctr shRNA were 
cultured on fluorescent gelatin in the presence or absence (ctr) of LPA(10/*M) or LPC -
egg (10/<M) and the percent of invadopodia-producing cells was determined; n=3. 
Western blot analysis of supernatants (S) and cell lysates (L) with antibodies directed 
against ATX was performed. Ratios of ATX to tubulin are shown. One representative blot 
of 2 is shown. D, Cell lines were cultured in invadopodia assays in the presence or 
absence (ctr) of LPC-egg (10//M) for 10 h (HT1080, A549, MDA-MB231) or 24 h (U-87, 
MCF-7). The percent of invadopodia-producing cells is shown; n=2-4. Columns, mean; 
bars,SEM; *,p<0M ; **,/?<0.001 ; ***,p<0.000l. 
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Figure 3. LPA4 is implicated in invadopodia production by HT1080 cells. 
A, ATX-overexpressing cells were treated with KH6425 (25/<M) for lOh in an 
invadopodia assay; n=3. B, LPA receptors were measured by RT-PCR; n=3. C, Effect of 
LPA4 shRNA on invadopodia production by unstimulated (ctr) or LPA (10uM) or 
LPC-18:1 (lOuM) stimulated cells; n=3-4. D, LPA4 mRNA was measured by RT-PCR; 
n=2. Columns, mean; bars, SEM; *,p<0M ; **,/><0.001 ; ***,p<0.0001. 
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LPC (Fig. 3C), indicating the important contribution of this receptor in ATX-induced 
invadopodia production. 
LPA4 has been shown to couple to the Gs family of G-proteins that triggers the 
activation of adenylyl cyclase resulting in an increase in cAMP accumulation (33). To 
verify the involvement of this pathway in invadopodia formation, ATX over-expressing 
cells were incubated overnight with cholera toxin (CTX) that interferes with Gs function. 
While short-term incubation with CTX is known to activate Gs, prolonged exposure 
ultimately results in its depletion (34). Depletion of Gs resulted in a drastic reduction of 
the percent of cells producing invadopodia (Fig. SI). Consistent with this result, we next 
investigated whether increasing intracellular levels of cAMP would result in increases in 
invadopodia formation. Exposing parental HT1080 cells to forskolin (an activator of 
adenylyl cyclase) or to dibutyryl cAMP (a stable analog of cAMP) resulted in 1.5-to 3-
fold increases in cells producing invadopodia (Fig. 4A). cAMP exerts its effects by 
activating the cAMP-dependent protein kinase A (PKA) and the recendy discovered 
exchange protein directly activated by cAMP (EPAC) (35). To determine which of these 
cAMP effectors was responsible for invadopodia production we took advantage of cAMP 
analogs known to specifically activate PKA (8-bromo-cAMP) or EPAC (8-pCPT). 
Results indicated that EPAC activation induced a 2.5-fold increase in invadopodia-
positive cells whereas PKA activation had no significant effect (Fig. 4B and C). In 
addition the PKA inhibitors H-89 and PKI did not affect ATX-induced invadopodia 
formation (Fig. S2), confirming the lack of involvement of PKA. To further assess the 
role of EPAC in invadopodia formation we transfected HT1080 cells with shRNA against 
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Figure 4. LPA4 signals through Gs-cAMP-EPAC for invadopodia production 
HT1080 cells were incubated with or without (ctr), forskolin or dibutyryl cAMP (A), 8-
pCPT (B), or 8-bromo cAMP (C) for 10 h in invadopodia assays; n=3-5. D, parental 
HT1080 or cells transfected with EPAC shRNA or ctr shRNA were cultured in the 
presence or absence (ctr) of LPA (10/iM) or LPC-18:1 (lOpiM) and the percent of 
invadopodia-producing cells was determined; n=3. Immunoprecipitation of EPAC from 
equal amounts of protein per sample is also shown. Columns, mean; bars, SEM; *, 
p<0.0l ; **,/?<0.001 ; ***,/?<0.0001. 
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EPAC and observed that EPAC inhibition reduced LPA- and LPC- induced matrix 
degradation (Fig. 4D). Taken together, the results suggested that invadopodia production 
by ATX is promoted by a Gs-cAMP-EPAC signaling pathway. 
Racl activation downstream of EPAC is required for invadopodia production. 
EPAC is a nucleotide exchange factor that activates the small G-protein Rapl. 
Selective inhibition of Rapl using GGTI-298 abolished EPAC-induced invadopodia 
production (Fig. S3), suggesting its involvement downstream of EPAC. Rapl has many 
effectors, including the small G-protein Racl (36), which can induce actin polymerization 
by the Arp2/3 complex, an event essential to invadopodia formation (37). We therefore 
used the Racl inhibitor, NSC23766, to investigate whether Racl could be a downstream 
target of EPAC for invadopodia production. Racl inhibition abolished 8-pCPT induced 
invadopodia production, whereas the effects induced by LPC and LPA were decreased by 
approximately 50% (Fig. 5A-C). These results suggested that although Racl appears to 
be the essential downstream mediator of EPAC and Rapl in invadopodia production, LPC 
and LPA might activate additional pathways that are independent of the EPAC-Racl 
interaction. 
LPA4 is implicated in 3D invasion and metastasis. 
After determining the implication of LPA4 in invadopodia formation we further 
investigated the contribution of this receptor in cell invasion through a 3D matrix and 
metastasis formation in vivo. For the invasion assay, parental HT1080 cells or cells 
transfected with LPA4 shRNA were seeded on top of a type I collagen matrix and 
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incubated with or without LPC and LPA. The results demonstrated that cells transfected 
with LPA4 shRNA lost the ability to invade deeply into a 3D matrix in response to LPC or 
LPA (Fig. 6A-B). Also, mice injected with LPA4 shRNA transfected cells developed 
significantly less lung metastasis compared to those injected with control shRNA (Fig. 
6C). These results indicated an essential role for LPA4 in HT1080 fibrosarcoma invasion 
both in vitro and in vivo and further strengthen the relevance of invadopodia formation 
for cancer cell invasion and metastasis. 
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Figure 5. Racl activation downstream of EPAC is required for invadopodia 
production. 
A, B, and C, HT1080 cells were incubated with the Rac-1 inhibitor (NSC23766) for 30 
min prior to stimulation with LPC-18:1 (10//M) (A), LPA (lO^M) (B), or 8-pCPT (50//M) 
(C), in invadopodia assays. The control (ctr) represents unstimulated HT1080 cells; 
n=3-4. Columns, mean; bars, SEM; *,p<0.01 ; **,/x0.001 ; ***,/?<().0001. 
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Figure 6. LPA4 is implicated in cell invasion in vitro and in vivo. 
A and B, Parental HT1080 or LPA4 shRNA-transfected cells were incubated on type I 
collagen in 3D invasion assays in the presence or absence (ctr) of LPA (10^M) or 
LPC-18:1 (10//M). Relative intensity of cell staining according to depth of invasion is 
shown (A), graph represents maximal depth of invasion (B); n=3. Columns, mean; bars, 
SEM; *,/?<0.01; **,p<0.001. C, CD1 nude mice were injected with HT1080 cells 
transfected with control shRNA (n=12) or LPA4 shRNA (n=12). The number of 
metastases counted on the lung surface for each mouse is shown. Results are from two 
separate experiments. Means +/- SEM are shown; *,/?=0.0008. 
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Supplementary Figure SI. Involvement of Gs and Gi in ATX-induced invadopodia 
production. 
A, For Gs depletion HT1080 cells over-expressing ATX were incubated overnight with 
CTX at the indicated concentrations. Cells were then plated on fluorescent gelatin in the 
presence or absence of CTX for lOh and the percentage of invadopodia-producing cells 
was calculated. B, ATX over-expressing HT1080 cells were incubated overnight with 
pertussis toxin (PTX) to inhibit Gi. Cells were plated on fluorescent gelatin in the 
presence or absence of PTX for lOh and the percentage of invadopodia producing cells 
was calculated. Columns, mean; bars, SEM; *,/x0.01 ; ***,/?<0.0001. 
Supplementary Figure S2. PKA inhibitors have no effect on ATX-induced 
invadopodia production. 
A and B, ATX over-expressing HT1080 cells were incubated in the presence or absence 
of PKA inhibitors, PKI (A) or H-89 (B) in invadopodia assays. The percent of 
invadopodia producing cells was calculated. Columns, mean; bars, SEM. 
Supplementary Figure S3. Rapl inhibition suppresses EPAC-induced invadopodia 
production. 
HT1080 cells were incubated with the Rap-1 inhibitor (GGTI-298) in the presence of 8-
pCPT (50//M) in invadopodia assays. The control (ctr) represents unstimulated HT1080 
cells. The percentage of invadopodia producing cells was calculated; n=3-4. Columns, 
mean; bars, SEM; *,p<0.0\ ; ***,/?<0.0001. 
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Discussion 
In this study, we demonstrated that ATX is implicated in the production of 
invadopodia and that this effect is dependent on the production of LPA from LPC, both of 
which can mediate invadopodia production in various cancer cell types expressing ATX 
and LPA receptors. We further provide the first evidence that LPA4 signaling regulates 
invadopodia formation downstream of ATX and LPA in HT1080 cells, a process mediated 
through the activation of EPAC by cAMP and subsequent Rac-1 activation. RNA 
interference experiments further support the requirement of LPA4 for in vitro cell invasion 
and in vivo metastasis. 
ATX and LPA have been shown to be involved in tumor invasion and metastasis 
(20, 21) and expression of ATX was correlated with increased invasion of many 
malignant cell lines (2-4). ATX is also known to augment functions associated with 
tumor progression and metastasis such as proliferation, survival, motility, invasion and 
angiogenesis. (9, 10, 12). A very recent study indicated that LPA can induce the 
formation of actin dots that resembles invadopodia (38). Here, we further showed that 
ATX, through the production of LPA, regulated the formation and function of the invasive 
structures, invadopodia, in tumor cells. Invadopodia are implicated in the first steps of 
mesenchymal invasion due to their ability to make cytoskeletal protrusions enriched in 
matrix degrading proteases (22, 23). The role of ATX in invadopodia production may be 
part of the mechanism to explain how ATX affects tumor cell invasion and metastasis 
LPA receptors have also been implicated in tumorigenesis. LPA has been shown in 
various studies to stimulate cell motility and to modulate tumor cell invasion, mediated 
mainly by LPAi and Gi/0 coupling protein (19, 39). LPA4, that we investigated in this 
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study, has so far been poorly linked to tumorigenesis. LPA4 is widely expressed in 
embryonic tissues and its mRNA expression has been shown to be increased at 
implantation sites in the uterus (33,40), suggesting a role in matrix degradation and 
invasion into the uterus wall. Among the few studies of LPA4 functions in tumor cells, the 
report of Lee et al. (41) suggests that LPA4 signaling inhibits cell motility and invasion by 
over-activation of RhoA and inhibition of PI3K resulting in decreased Racl activation. 
Conversely, LPA4 has been shown to induce cell transformation and anchorage 
independent growth in Myc-transformed cells (42). Our finding that LPA4 is implicated 
in the formation of invadopodia through Gs signaling provides a novel role for this LPA 
receptor and adds an alternative pathway by which ATX and LPA can favor tumor 
invasion. The discrepancy between our results and those of Lee et al. (41), showing a 
negative role for LPA4 in the regulation of motility and invasion, may be due to the fact 
that these authors used a LPA4 over-expressing cell type in which the LPA4 response is 
coupled to Gq and G12/13 but does not mediate effects through Gs as suggested herein with 
endogenously LPA4 expressing HT1080 cells. 
In addition to the role of LPA4 in tumor invasion, one important observation of our 
study is the finding that cAMP and EPAC are involved in invadopodia production. 
Although the role of cAMP in various cell functions has been studied for decades, 
information regarding its contribution to cell invasion is scarce. Increases in cAMP have 
previously been correlated with anti-invasiveness of intestinal cancer cells (43). 
However, many of the effects of cAMP seem to be contradictory and depend on the cell 
types studied. For example, depending on cell context, cAMP either stimulates or inhibits 
cell division. It also causes reversion to a normal phenotype in some transformed cells, 
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while being important for differentiation of many cell types (44). These observations may 
be related to the independent or opposing functions of the two main effectors of cAMP, 
PKA and EPAC (35). Here, we clearly showed that cAMP accumulation led to the 
production of invadopodia structures and that downstream activation of EPAC and Rapl, 
but not PKA, were involved in this function. EPAC is an established GEF for Rap-1, a 
small GTPase, which has been implicated in malignancy (36) mainly through the inside-
out activation of integrins that are associated with cell invasion (45). Invadopodia 
structures are enriched in integrins that interact with the metalloproteinase MT1-MMP to 
trigger cancer cell invasion (46). It is therefore possible that one of the mechanisms by 
which EPAC affects invadopodia formation is through the inside-out activation of 
integrins by Rap-1. 
We also observed that invadopodia formation induced by EPAC was dependent on 
Racl activation. Rapl is know to activate Racl indirectly, through integrin signaling, or 
more direcdy, due to the activation of the Rapl effectors Vav2 and Tiam (45). Recently 
EPAC and Rapl have been implicated in translocation of Racl to the cell membrane, 
resulting in the recruitment of the Rac effector cortactin (47). Because Rapl as well as 
EPAC activities are spatially regulated in cells (48), it is possible that specific activation 
of EPAC-Rapl at sites of invadopodia formation could result in translocation of Racl to 
these sites, leading to the recruitment of cortactin, an essential component of forming 
invadopodia. Our findings that stimulation of the cAMP-EPAC pathways affects 
invadopodia production through Rac-1 activation identifies an alternative pathway for the 
activation of Rac-1 at the sites of invadopodia formation. 
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Whereas Racl inhibition abolished EPAC-induced invadopodia production, the 
effects of LPC and LPA were only reduced by approximately 50%. These observations 
suggested that LPC and LPA triggered the activation of pathways that were independent 
of the EPAC-Racl axis. In support of this, our results further showed a minor role for the 
Gi G-protein in invadopodia formation (SI). It is possible that in addition to Gs, Gi could 
also couple to LPA4 due to Gs/Gi switching, a phenomenon whereby phosphorylation of 
the receptor causes it to switch coupling specificity from Gs to Gi (49). In addition, 
preliminary results from our laboratory (Harper et al. unpublished) indicate that inhibition 
of Rock, a downstream effector of RhoA, but not PI3K, causes a partial decrease in 
invadopodia formation induced by ATX. This would implicate a potential involvement 
of the Rock pathway as well as other LPA receptors such as LPAi or LPA2 in invadopodia 
formation, which remains to be further elucidated. 
To date studies have indicated that LPA is involved in growth and metastasis of 
various cancers including ovarian and breast mainly through its action on LPA1-3 
receptors (20,21, 39). The expression of LPA receptors is cell-specific, and each can 
elicit different and to some extent overlapping responses upon LPA binding (13,19). Our 
work presents evidence that inhibition of the LPA receptor LPA4 could provide an 
additional tool to improve the efficacy of treatment of metastasis. Because LPA receptors 
and ATX are currently being targeted in preclinical trials, (50), the current findings should 
stimulate studies to evaluate the expression pattern and clinical outcome of LPA4, 
together with other LPA receptors and ATX, in various cancer patients. 
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3 - DISCUSSION 
Metastasis is the leading cause of cancer patient mortality and is a complex process that 
involves many steps in order for the cells to reach other parts of the body. One important 
step in the process of metastasis is the degradation of surrounding ECM and basement 
membranes. This allows the tumor cells to leave the original tumor site and enter blood 
or lymphatic vessels in order to travel to distant sites in the body where they will again 
need to degrade surrounding tissues to invade and form a new tumor (WOODHOUSE et 
al, 1997). Invadopodia are invasive structures that are thought to be responsible for this 
degradative capacity of cancer cells and are therefore thought to be implicated in an 
important step of metastasis (BASBAUM and WERB, 1996;CONDEELIS and SEGALL, 
2003). 
In the manuscript presented herein, we have shown that LPA4 is implicated in 
invadopodia production. LPA4 is also important for invasion into a 3D matrix as well as 
metastasis formation in a mouse model, further correlating the relationship between 
invadopodia production and metastasis formation. Furthermore, ATX through the 
production of LPA and downstream signaling through LPA4, was found to be implicated 
in invadopodia biogenesis by cancer cells. Invadopodia are complex structures that 
require the coordinated action of many proteins and signaling molecules in a small 
subcellular space (GIMONA and BUCCIONE, 2006). Therefore the mechanisms that 
promote the specific localization of the proteins and signaling molecules discussed in this 
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paper, including ATX, LPA4 and cAMP-EPAC-Racl, could potentially explain in part 
why ATX is able to promote invadopodia production. 
The effect of ATX on invadopodia biogenesis may be due in part to increased localized 
secretion of ATX towards sites of forming invadopodia. In various studies, the Golgi 
apparatus has been shown to reorient toward and come in close proximity to invadopodia 
(BALDASSARRE et al, 2003). Because ATX follows the classical secretory pathway 
for its secretion, this might allow the concentrated delivery of ATX-containing vesicles 
toward the extracellular space surrounding invadopodia. Another possibility is that 
secreted ATX could remain near invadopodial structures, by binding to integrins, which 
were found enriched at invadopodia (CHEN, 1990). ATX has potential RGD and LDV 
integrin-binding sites (KANDA et al, 2008), and its binding to activated integrins was 
recently shown to be a mechanism that targets secreted ATX to lymphocytes undergoing 
recruitment and promotes their entry into secondary lymphoid organs (KANDA et al, 
2008). Either of these possibilities or both could lead to an increased local production of 
LPA by ATX in the vicinity of forming invadopodia that could then signal via GPCRs to 
promote further invadopodia formation. To determine the implication of integrins on 
ATX localization and its effect on invadopodia, one possibility is to use integrin-directed 
antibodies or integrin blocking peptides in the invadopodia assay, similar to those used in 
the study by Kanda et al. However this approach is non-specific and would likely result 
in reduced cell attachment, among other effects. To increase the specificity, we could 
perform mutagenesis experiments to mutate the RGD and/or LDV binding sites in ATX 
and compare the impact of overexpressed wild type or mutated ATX on invadopodia 
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production. In order to determine if there is directed secretion or binding of ATX to 
invadopodia sites we could also perform fluorescence or confocal microscopy to visualize 
the localization of ATX in cells forming invadopodia in conjunction with secretion/ 
recycling vesicles or plasma membrane markers. We can further use these microscopy 
techniques to determine the effect of the above-mentioned integrin binding site mutations 
on ATX localization. 
LPA might also promote invadopodia formation due to a specific relocalization or 
targeting of LPA receptors to sites of forming invadopodia, resulting in enhanced LPA 
signaling at invadopodia. GPCRs and G-proteins are known to be localized to specific 
lipid domains and lipid rafts are thought to regulate their signaling cascades (ALLEN et 
al, 2007;PATEL and INSEL, 2009). For example, the delta-opioid receptor, when 
activated, is found concentrated in sphingomyelin enriched bilayers (i.e. lipid rafts) 
(ALVES et al, 2005). Gs trafficking has also been shown to be regulated by caveolin-1 
and lipid microdomains (ALLEN et al, 2009). Lipid rafts are specialized lipid 
microdomains enriched in cholesterol, saturated lipids (sphingolipids) and raft-associated 
proteins that include caveolin-1 (BROWN and LONDON, 1998;SIMONS and IKONEN, 
1997). They also contain glycosyl-phosphatidylinositol anchored proteins, are associated 
with the cytoskeleton, and are resistant to detergent extraction (BROWN et al, 2000). 
Lipid rafts have been implicated in signal integration, membrane trafficking, and protein 
sorting (JACOBSON et al, 2007;MAYOR and RAO, 2004;SIMONS and TOOMRE, 
2000). The lipid raft/caveolae domains are thought to compartmentalize proteins 
involved in specific signaling tasks. Cholesterol increases rigidity of the membrane 
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therefore regulating lateral mobility and compartmentalization of proteins. This can 
affect the probability of receptor interaction with downstream signaling partners and 
optimize their spatiotemporal interactions to increase signaling efficiency (SIMONS and 
TOOMRE, 2000). Furthermore, cholesterol may play a role in stabilizing the 
conformation of some GPCRs (ALBERT and BOESZE-BATTAGLIA, 
2005;SCHERTLER and HARGRAVE, 2000). 
Invadopodial structures have recently been associated with increases in cholesterol and 
caveolin. Therefore, invadopodia seem to have specific lipid characteristics similar to 
lipid rafts. Caveolin-1 has been determined to be a regulator of invadopodia biogenesis 
by modulating lipid domains through the transport of cholesterol (CALDIERI et al, 
2009b), while lipid rafts and caveolin-1 were shown to be required for invadopodia 
formation and subsequent ECM degradation by human breast cancer cells 
(YAMAGUCHI et al, 2009). In the study of Yamaguchi et al., lipid rafts were found to 
be enriched, internalized, and dynamically trafficked at invadopodia sites. Furthermore, 
various invadopodia-associated components such as cortactin and MT1-MMP were found 
localized in lipid raft enriched membrane fractions (CALDIERI et al., 
2009b;YAMAGUCHI et al, 2009). Therefore, specific GPCRs, for example LPA4 in the 
case of this memoire, could potentially be localized to, or trafficked in, lipid rafts at 
invadopodia leading to enhanced signaling. This could account for localized cytoskeletal 
rearrangements induced by LPA signaling that are required for invadopodia formation. To 
verify if LPA4 is localized to invadopodia and whether this is dependent on lipid rafts we 
could perform fluorescence microscopy to visualize the localization of LPA4 along with 
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invadopodia markers. We could then use techniques to disrupt lipid rafts, such as 
cholesterol sequestration, and determine the effect on LPA4 localization. 
Spatial regulation of numerous signaling and effector molecules is another important 
aspect of invadopodia formation as it requires the coordinated action of many different 
signaling pathways in a specific cellular space (GIMONA and BUCCIONE, 2006). This 
ties in well with the cAMP-EPAC-Rapl pathway found to be implicated in our work. It is 
well known that cAMP and its effectors, EPAC (PONSIOEN et al, 2009) and PKA, 
undergo tight spatial and temporal regulation (JARNAESS and TASKEN, 2007) to 
promote different cellular functions. As mentioned in the introduction, the EPAC effector 
Rapl influences Racl activation by the re localization of the Racl effectors Vav2 and 
Tiaml to sites of membrane protrusion actively engaging the ECM, in Hela cells 
(ARTHUR et al, 2004). Invadopodia can be considered to be membrane protrusions 
engaging the ECM which leads us to speculate that there could be specific activation of 
Racl by its effectors Vav2 and Tiaml, induced by EPAC-Rapl signaling, at sites of 
invadopodia production. Furthermore, EPAC activation has been shown to induce Racl 
translocation to the cell membrane in microvascular endothelium resulting in recruitment 
of cortactin to the cell membrane, an important component of invadopodia (BAUMER et 
al, 2008). Therefore, the postulated specific localization of either ATX or LPA4 would 
lead to activation of the cAMP pathway in the vicinity of invadopodia. Due to the spatial 
regulation of cAMP and its effectors the signaling induced by the cAMP pathway would 
then be efficiently confined to the area of invadopodia production, specifically the cell 
membrane. 
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In addition to promoting actin rearrangement essential for invadopodia formation, ATX 
may also stimulate invadopodia functions. ATX has been shown to increase the 
expression of uPA through a Gi-PI3K-Akt-NFkB signaling pathway in human melanoma 
cells (LEE et al, 2006). LPA is also capable of increasing uPA activity in ovarian cancer 
cells, through Ras-Raf signaling, as well as in endometrial carcinoma cells (LI et al, 
2005;WANG et al, 2010). As discussed in the introduction section, uPA is a serine 
protease that interacts with uPAR to convert plasminogen to plasmin which degrades 
collagen type IV, fibronectin and laminin as well as activating MMP-2, -3, -9 and uPA 
(DANO et al, 1985;LIJNEN, 2001;SCHMITT et al, 1992). Complexes containing 
uPAR and seprase (another serine proteinase) have been localized to invadopodia with 
this association being dependent on the microtubule cytoskeleton and integrins (ARTYM 
et al, 2002). Interestingly, uPAR is a GPI-linked transmembrane protein and has 
therefore been associated with caveolae and lipid rafts, which are enriched at invadopodia 
(STAHL and MUELLER, 1995). This involvement of uPA in invadopodia function is an 
interesting avenue to further explore. Whether this would imply LPA4 or other LPA 
receptors remains to be elucidated. 
Supplementary results of the manuscript presented herein suggest an implication of other 
receptors in ATX-induced invadopodia production. For example, inhibition of Gi with 
PTX was found to partially inhibit ATX-induced invadopodia production. Inhibition of 
Rock, a downstream effector of G12/13-RI10A, also partially decreased ATX effects. 
Because Gi and G12/13 seem to be partially implicated in invadopodia production, we 
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believe that in addition to LPA4, LPAi and LPA2, which can signal through both of these 
G-proteins, could also be involved. In the article by Taghavi et al., in which LPA4 
expression was found to induce transformation and anchorage independent growth, LPA 
receptors 1 and 2, but not 3, were shown to mediate a similar effect (TAGHAVI et al, 
2008). LPAi and LPA2 have also been highly implicated in tumorigenesis, migration and 
invasion of many cancer cell types. For example, LPAi is involved in promoting motility 
of human pancreatic cancer cells (YAMADA et al, 2004), neoplastic cells (HAMA et al, 
2004) and breast cancer cells (HORAK et al, 2007), as well as metastasis of human colon 
cancer cells (SHIDA et al, 2003) and breast cancer cells (BOUCHARABA et al, 2006). 
LPA2 has been implicated in mitogenic signaling of human colon cancer cells (YUN et 
al, 2005) as well as mediating cell motility of ovarian cancer cells (JEONG et al, 2008). 
Therefore signaling pathways of multiple LPA receptors might also play a role in the 
metastatic cascade by promoting migration following invadopodia-mediated ECM 
degradation. It is important to note that in our study we used HT1080 fibrosarcoma cells 
that have high expression of LPA4 and low expression of LPA1-3. However, any of the 
LPA1-3 receptors could potentially be upregulated by invadopodia signaling events or 
extracellular cues from the degraded matrix during invadopodia-mediated degradation. 
Therefore, LPA4 through Gs-cAMP signaling and Rapl-Racl activation might lead to 
increased invadopodia formation and subsequent activation of other LPA receptors might 
then promote migration of the cell through the matrix that has been degraded. 
In this memoire, we have added both LPC, the substrate, and LPA, the product of ATX 
activity, to invadopodia assays to determine their effects. In our first experiments, we 
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used a natural source of LPC derived from egg yolk, that was prepared by the action of 
phospholipase A on egg L-a-phosphatidylcholine (LPC-egg), that unexpectedly induced 
dramatically more invadopodia production than LPA in the same experiments (Fig. 2C). 
In order to understand these results and to be more rigorous, we changed our source of 
LPC for a synthetic reagent with the same hydrophobic tail length and degree of 
unsaturation as the LPA. Using synthetic LPC (18:1) and LPA (18:1), we observed that 
both LPC and LPA, used at the same concentration, induced similar percentages of cells 
to produce invadopodia. However, in the literature, LPA has been shown to be much 
more potent than LPC in inducing cell migration often measured by a wound healing 
assay. In these publications, LPA was shown to be maximally effective at 0.5 uM, while 
LPC required 5-10 uM concentrations for a similar effect (GAETANO et al, 2009). In 
order to determine why our results differed from those of other authors, we tested the 
effects of LPC and LPA in a wound healing assay. Using this assay, we observed that for 
the same concentration of reagents used, LPA had a stronger impact on cell migration 
than LPC, as measured by the number of cells that had moved into the scratch area 
(Harper et al., unpublished results). Therefore, it seems that the observed discrepancy 
can neither be attributed to the cell type, nor to the source of LPC and LPA, but possibly 
to the biological assay used. One possibility for the strong response to LPC in the 
invadopodia assay could be due to the postulated relocalization of ATX and LPA receptors 
at sites of forming invadopodia (as discussed above). In this scenario, ATX might produce 
LPA from the added LPC in closer proximity to the responding receptor, thereby requiring 
less LPC. 
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In this memoire, we have studied the roles of ATX, LPA and the LPA GPCR LPA4 in 
tumor cell invasion and invadopodia production in HT1080 cells. We have discovered a 
novel role for LPA4 and cAMP-EPAC-Racl signaling in ATX-induced invadopodia 
production. Each of these proteins and signaling molecules can be spatially regulated by 
various mechanisms. It will be interesting to determine in future studies whether ATX 
and molecules involved in the LPA4 signaling pathway are spatially regulated during 
invadopodia formation and to define the mechanisms involved. 
From a more clinical or physiological point of view, finding a way to target and inhibit 
the production of invadopodia by cancer cells could be a good way to prevent the 
metastasis of tumor cells. Without invadopodia the tumor cells should no longer be able 
to cross high-density matrix such as basement membranes and this should therefore 
prevent their migration and invasion to distant sites. Furthermore invadopodia are non-
essential structures that are not formed by normal cells and therefore targeting them 
would likely result in fewer side effects than conventional chemotherapies and should not 
affect non-cancerous cells (WEAVER, 2006). 
In this study we have found that blocking LPA4 or ATX could provide new targets to 
potentially inhibit the production of invadopodia by cancer cells. LPA4 is one of the more 
recently identified LPA receptors and therefore there is little information on the 
implications of this receptor in physiology and disease. LPA4 is highly expressed in 
embryonic tissues while in adults it has low expression in many tissues (LEE et ah, 
2007;NOGUCHI et a!., 2003). Studies so far have found that it has a role in neuronal 
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development and bone homeostasis and possibly during pregnancy (ISHII et al, 
2009;LIU et al, 2010;YANAGIDA et al, 2007). Due to the findings of our current work 
it will be interesting to further investigate the roles of LPA4 and determine if this receptor 
is essential for other biological functions in the adult. It will also be interesting to 
determine why LPA4 is over-expressed in many cancer cell lines and if factors in the 
tumor microenvironment can cause an increase in LPA4 expression levels. As LPA4 is 
highly expressed in a wide range of highly invasive cancers such as ovarian, 
glioblastoma, colon, fibrosarcoma, lung, prostate and melanoma (KISHI et al, 2006), the 
results presented herein can be postulated to apply to a variety of cancers. Further studies 
are needed to determine which cells types are affected by LPA4 knockdown and if the 
cAMP-EPAC-Racl pathway is used by different cell lines to promote invadopodia 
production. 
LPA receptors (1-3) and ATX are currently being targeting in preclinical trials to treat 
cancer (MURPH and MILLS, 2007) so the design and utilization of inhibitors that also 
target LPA4 could be beneficial as it seems to mediate signaling through a different 
pathway than the other LPA receptors. ATX and LPA4 are both highly expressed during 
embryogenesis but in the adult have a lower and more restricted expression. Their over-
expression may therefore be a good determinant for identifying potentially aggressive 
cancers. Early detection of cancer cells that possess metastatic potential could improve 
the treatment and prognosis of this disease. Metastasis is a complicated process yet to be 
fully understood. The results of our study will hopefully help shed some new light on this 
process. 
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